{"text": "For trials of high - intensity therapy ( INR 2.8 to 4.8 ) , although there was a reduction in mortality and thromboembolic complications , there was a sixfold increase in major bleeding ( from 0.7 to 4.6 % ) .", "label": "", "metadata": {}, "score": "37.980896"}
{"text": "However , in clinical practice the use of anticoagulative agents seems to be much more heterogeneous [ 9 ] .Some authors have reported a significantly higher incidence of parenchymal haematomas if thrombolysis was immediately followed by intravenous or subcutaneous heparin administration [ 10 ] .", "label": "", "metadata": {}, "score": "41.381927"}
{"text": "Further known vascular risk factors were hypertension and smoking .Even so , the patient took no medication at the time of admission .Thrombolysis with 70 mg rt - PA ( 0.9 mg / kg ) was started two hours after the onset of symptoms .", "label": "", "metadata": {}, "score": "41.942394"}
{"text": "Diabetes and long - term outcome .Follow - up data were available at a mean of 1,201 \u00b1 441 days .These results were confirmed in patients receiving BMS or DES , except for TVR , in which no difference was observed between diabetic and nondiabetic patients treated with DES ( Fig . 2 ) .", "label": "", "metadata": {}, "score": "42.11155"}
{"text": "The primary endpoint was a composite of all cause death , myocardial infarction or any revascularization at one year .After one year , both the conservative strategy group and aggressive strategy group had similar rates of adverse events ( 7.3 percent vs. 6.8 percent , respectively ) .", "label": "", "metadata": {}, "score": "42.61788"}
{"text": "The main finding of the current study was that diabetes was associated with a significantly higher mortality , reinfarction , TVR , and stent thrombosis .", "label": "", "metadata": {}, "score": "42.699265"}
{"text": "( 7 ) found that among patients treated with glycoprotein IIb - IIIa inhibitors , diabetes was associated with higher occurrences of distal embolization and impaired myocardial reperfusion and higher mortality .", "label": "", "metadata": {}, "score": "42.802612"}
{"text": "View Article PubMed .Nilsen DW , Goransson L , Larsen AI , Hetland O , Kierulf P : Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction .", "label": "", "metadata": {}, "score": "43.114037"}
{"text": "Smith et al 82 reported the results of a randomized trial that renewed interest in the long - term use of oral anticoagulants after myocardial infarction .", "label": "", "metadata": {}, "score": "43.510704"}
{"text": "The bleeding outcomes from these clinical trials 147 - 150 are shown in Table 8 .For IV unfractionated heparin , the rates of major bleeding range from 0 to 6.3 % during the initial 8 days of treatment , and from 0.3 to 3.2 % during the long - term treatment phase between approximately 1 week and 3 months .", "label": "", "metadata": {}, "score": "43.626198"}
{"text": "Further improvement has been obtained by optimization of antithrombotic therapies and adjunctive mechanical devices ( 3 - 5 ) .Special attention has been given in the last years to diabetes , because it has been associated with higher rates of impaired reperfusion , mortality , and target vessel revascularization ( TVR ) after primary angioplasty ( 6 - 8 ) .", "label": "", "metadata": {}, "score": "43.88202"}
{"text": "More recently , Agnelli et al 118 randomized patients with idiopathic deep vein thrombosis to discontinue treatment with oral anticoagulants after 3 months or to continue receiving therapy ( INR 2.0 to 3.0 ) for an additional 9 months having completed an initial 3 months of treatment .", "label": "", "metadata": {}, "score": "44.209335"}
{"text": "In the study by Hull et al , 6 that compared two intensities of oral anticoagulation , the frequency of total bleeding was also substantially lower with the less intense regimen ( 4 % vs 22 % ) , without being associated with a loss of antithrombotic efficacy .", "label": "", "metadata": {}, "score": "44.213844"}
{"text": "The fluid balance was continuously monitored and kept net 0 ml/24 hours to avoid fluid overload .On the 3 rd day after admission , the patient developed acute dyspnea , tachypnea , tachycardia , and an elevated blood pressure .", "label": "", "metadata": {}, "score": "44.25187"}
{"text": "In prior studies , 11 , 17 - 18 , 57 previous stroke has not been identified as a risk factor for intracerebral bleeding in orally anticoagulated patients with atrial fibrillation ( INR 1.4 to 4.5 ; see chapter on \" Antithrombotic Therapy in Atrial Fibrillation \" ) .", "label": "", "metadata": {}, "score": "44.68048"}
{"text": "Major bleeding occurred more frequently in patients who were treated with long - term anticoagulation ( 2.4%/yr vs 0.7%/yr ) .Kearon et al 117 randomized patients with a first episode of idiopathic venous thromboembolism to remain on a regimen of warfarin ( INR 2.0 to 3.0 ) or to receive placebo for an additional 2 years following an initial 3 months of anticoagulation .", "label": "", "metadata": {}, "score": "45.083763"}
{"text": "The procoagulant response to rt - PA has been shown to persist up to 72 hours [ 3 ] .Otherwise , clinical studies of fibrinolytic therapy in myocardial infarction show , that early heparin treatment starting immediately after thrombolysis significantly decreases the risk of cardiac vessel reocclusion [ 5 ] .", "label": "", "metadata": {}, "score": "45.16585"}
{"text": "The mean follow - up period was 37 months .Seventy - three patients ( 4.3 % ) in the anticoagulant group experienced major bleeding compared with 19 placebo - treated patients ( 1.1 % ) .", "label": "", "metadata": {}, "score": "45.321377"}
{"text": "For moderate - intensity to high - intensity therapy vs aspirin , there was a 2.4-fold increase in major bleeding ( from 1.0 to 3.7 % ) .", "label": "", "metadata": {}, "score": "46.319374"}
{"text": "In stroke patients with an occlusion in the posterior cerebral circulation undergoing intra - arterial thrombolysis , heparin treatment is also known to reduce the rate of early reocclusion [ 6 ] .", "label": "", "metadata": {}, "score": "46.73613"}
{"text": "The patient 's history and risk profile suggests an increased risk for cardiac events [ 14 ] .The transient increase of D - Dimer probably indicates the state of hypercoagulability after rt - PA treatment [ 3 ] .", "label": "", "metadata": {}, "score": "46.968716"}
{"text": "Lindmarker , P , Holmstro\u0308m , M , Granqvist , S , et al Comparison of once - daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis .", "label": "", "metadata": {}, "score": "46.970562"}
{"text": "Lindmarker , P , Holmstro\u0308m , M , Granqvist , S , et al Comparison of once - daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis .", "label": "", "metadata": {}, "score": "46.970562"}
{"text": "In studies that have used less intense anticoagulation , low rates of warfarin - related bleeding have been observed in patients with ischemic cerebrovascular disease 12 , 18 or venous thromboembolism .", "label": "", "metadata": {}, "score": "47.28395"}
{"text": "This is probably due to inclusion in the more recent studies 151 - 153 of patients who undergo cardiac catheterization or coronary bypass surgery ; much of the major bleeding in these trials was associated with invasive vascular procedures or coronary bypass surgery .", "label": "", "metadata": {}, "score": "47.517754"}
{"text": "The results showed that the 40 mg and 50 mg doses were similar to accelerated infusion of Activase in restoring patency .TIMI Grade 3 flow and TIMI Grade 2/3 flow at 90 minutes are shown in Table 2 .", "label": "", "metadata": {}, "score": "47.52904"}
{"text": "N Engl J Med1989;320,352 - 394 .Klein , W , Buchwald , A , Hillis , SE , et al Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease : Fragmin in unstable coronary artery disease study .", "label": "", "metadata": {}, "score": "48.019424"}
{"text": "N Engl J Med1989;320,352 - 394 .Klein , W , Buchwald , A , Hillis , SE , et al Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease : Fragmin in unstable coronary artery disease study .", "label": "", "metadata": {}, "score": "48.019424"}
{"text": "Three randomized trials have compared a short duration ( 4 weeks 113 - 114 or 6 weeks 115 ) with a medium duration ( 3 months 113 - 114 or 6 months 115 ) of less intense oral anticoagulation for the treatment of venous thromboembolism .", "label": "", "metadata": {}, "score": "48.044407"}
{"text": "In this review , the incidence of hemorrhage in patients receiving oral anticoagulants or heparin and the clinical and laboratory risk factors that predispose to bleeding are discussed .", "label": "", "metadata": {}, "score": "48.64675"}
{"text": "Bulsara , et al .: Use of the peak troponin value to differentiate myocardial infarction from reversible neurogenic ventricular dysfunction associated with aneurysmal subarachnoid hemorrhage .", "label": "", "metadata": {}, "score": "48.87408"}
{"text": "Kuijer et al 30 recently developed another prediction model based on age , gender , and the presence of malignancy .In patients classified at high , middle , and low risk , the frequency of major bleeding was 7 % , 4 % , and 1 % , respectively after 3 months of therapy .", "label": "", "metadata": {}, "score": "48.89978"}
{"text": "In the two studies combined , the case - fatality ratio of major bleeding in patients receiving anticoagulant medication was 15 % ( 2 of 13 patients ) .", "label": "", "metadata": {}, "score": "48.95674"}
{"text": "Case presentation .We report a 61-year - old man who developed an acute global aphasia and right - sided hemiparesis .Cranial CT was normal and systemic thrombolytic therapy with tPA was started 120 minutes after symptom onset .", "label": "", "metadata": {}, "score": "49.652878"}
{"text": "Levine , MN , Hirsh , J , Gent , M , et al Optimal duration of oral anticoagulant therapy : a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis .", "label": "", "metadata": {}, "score": "49.97644"}
{"text": "Levine , MN , Hirsh , J , Gent , M , et al Optimal duration of oral anticoagulant therapy : a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis .", "label": "", "metadata": {}, "score": "49.97644"}
{"text": "In a trial conducted by the Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis ( ASPECT ) investigators , patients who had sustained a myocardial infarction were randomized to either oral anticoagulant therapy at a targeted INR of 2.8 to 4.8 or placebo treatment .", "label": "", "metadata": {}, "score": "49.99904"}
{"text": "Levine , M , Gent , M , Hirsh , J , et al A comparison of low - molecular - weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep - vein thrombosis .", "label": "", "metadata": {}, "score": "50.137802"}
{"text": "Levine , M , Gent , M , Hirsh , J , et al A comparison of low - molecular - weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep - vein thrombosis .", "label": "", "metadata": {}, "score": "50.137802"}
{"text": "For IV unfractionated heparin , the rates of major bleeding range from 0 to 7 % and the rates of fatal bleeding range from 0 to 2 % .", "label": "", "metadata": {}, "score": "50.19328"}
{"text": "Systemic rt - PA thrombolysis in acute stroke has been implemented into daily clinical practice during the last decade .The treatment within three hours of stroke appears to be effective in reducing the neurological deficit [ 1 , 7 ] .", "label": "", "metadata": {}, "score": "50.20848"}
{"text": "74 The rates of major bleeding were low in these studies ( Table 2 ) .There are 10 published randomized trials of long - term oral anticoagulant therapy in patients with acute myocardial infarction 42 , 82 - 92 ( Table 3 ) .", "label": "", "metadata": {}, "score": "50.253853"}
{"text": "Blackshear , JL , Baker , VS , Holland , A , et al Fecal hemoglobin excretion in elderly patients with atrial fibrillation : combined aspirin and low - dose warfarin vs conventional warfarin therapy .", "label": "", "metadata": {}, "score": "50.275517"}
{"text": "Blackshear , JL , Baker , VS , Holland , A , et al Fecal hemoglobin excretion in elderly patients with atrial fibrillation : combined aspirin and low - dose warfarin vs conventional warfarin therapy .", "label": "", "metadata": {}, "score": "50.275517"}
{"text": "For TNKase - treated patients in ASSENT-2 , the incidence of intracranial hemorrhage was 0.9 % and any stroke was 1.8 % .The incidence of all strokes , including intracranial bleeding , increases with increasing age ( see PRECAUTIONS : Geriatric Use ) .", "label": "", "metadata": {}, "score": "50.581375"}
{"text": "Rethrombosis or new thrombus formation might be an underestimated complication of rtPA therapy and potentially explain cases of secondary stroke progression .Early systemic anticoagulation with heparin might reduce the risk of rethrombosis but also increase the risk of a bleeding complication .", "label": "", "metadata": {}, "score": "50.656223"}
{"text": "In two meta - analyses , 79 , 81 of 12 trials of warfarin for stroke prevention , warfarin increased the odds of major bleeding ( odds ratio of 1.90 and relative risk of 2.4 , respectively ) ; the absolute risk increase was 0.3%/yr .", "label": "", "metadata": {}, "score": "50.663418"}
{"text": "Serial TTE performed two days later revealed complete resolution of the thrombus and hypokinesia ; with a left ventricular ejection fraction of 40 % .In the mean time the patient recovered from the acute cardiac decompensation .", "label": "", "metadata": {}, "score": "50.721634"}
{"text": "The data in Table 8 support the inference that LMW heparin does not result in an increased risk of major bleeding compared with IV unfractionated heparin .", "label": "", "metadata": {}, "score": "50.83403"}
{"text": "In one of these studies , for example , the frequency of major bleeding decreased from 3.0 % during the first month of outpatient warfarin therapy to 0.8%/mo during the rest of the first year of therapy and to 0.3%/mo thereafter .", "label": "", "metadata": {}, "score": "51.16724"}
{"text": "Koopman , MMW , Prandoni , P , Piovella , F , et al Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low - molecular - weight heparin administered at home .", "label": "", "metadata": {}, "score": "51.188065"}
{"text": "Koopman , MMW , Prandoni , P , Piovella , F , et al Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low - molecular - weight heparin administered at home .", "label": "", "metadata": {}, "score": "51.188065"}
{"text": "In addition , there is good evidence that serious bleeding during heparin treatment can occur when the anticoagulant response is in the therapeutic range .4 In summary , there was an increased rate of major bleeding with intermittent IV heparin compared with continuous IV infusion .", "label": "", "metadata": {}, "score": "51.287777"}
{"text": "In a previous report , De Luca et al .( 35 ) found that BMS did not provide significant benefits in outcome as compared with balloon angioplasty in unselected diabetic patients undergoing primary angioplasty .", "label": "", "metadata": {}, "score": "51.297844"}
{"text": "Serial further TTE investigations demonstrated a complete resolution of the thrombus and normalisation of LVEF within two days .Conclusion .Our case demonstrates an intracardiac thrombus formation following rtPA treatment of acute stroke , probably caused by secondary hypercoagulability .", "label": "", "metadata": {}, "score": "51.39727"}
{"text": "Hellemons , BS , Langenberg , M , Lodder , J , et al Primary prevention of arterial thromboembolism in non - rheumatic atrial fibrillation in primary care : randomised controlled trial comparing two intensities of coumarin with aspirin .", "label": "", "metadata": {}, "score": "51.408737"}
{"text": "Hellemons , BS , Langenberg , M , Lodder , J , et al Primary prevention of arterial thromboembolism in non - rheumatic atrial fibrillation in primary care : randomised controlled trial comparing two intensities of coumarin with aspirin .", "label": "", "metadata": {}, "score": "51.408737"}
{"text": "Dolovich , LR , Ginsberg , JS , Douketis , JD , et al A meta - analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism .", "label": "", "metadata": {}, "score": "51.41297"}
{"text": "Dolovich , LR , Ginsberg , JS , Douketis , JD , et al A meta - analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism .", "label": "", "metadata": {}, "score": "51.41297"}
{"text": "Altman , R , Rouvier , J , Gurfinkel , E , et al Comparison of high dose with low dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulants . Circulation1996;94,2113", "label": "", "metadata": {}, "score": "51.425575"}
{"text": "Altman , R , Rouvier , J , Gurfinkel , E , et al Comparison of high dose with low dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulants . Circulation1996;94,2113", "label": "", "metadata": {}, "score": "51.425575"}
{"text": "Fihn , SD , McDonnel , M , Martin , D , et al Risk factors for complications of chronic anticoagulation : a multicenter study : Warfarin Optimized Outpatient Follow - up Study Group .", "label": "", "metadata": {}, "score": "51.456863"}
{"text": "Fihn , SD , McDonnel , M , Martin , D , et al Risk factors for complications of chronic anticoagulation : a multicenter study : Warfarin Optimized Outpatient Follow - up Study Group .", "label": "", "metadata": {}, "score": "51.456863"}
{"text": "Less intense warfarin therapy has also been administered to other groups of patients with very low rates of major bleeding .11 In patients with atrial fibrillation , an INR of 2.5 ( range , 2.0 to 3.0 ) minimizes the risk of either hemorrhage or thromboembolism .", "label": "", "metadata": {}, "score": "51.47139"}
{"text": "Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST - elevation myocardial infarction with versus without diabetes mellitus .Am J Cardiol 2005 ; 95 : 1375 - 1377 pmid : 15904649 .", "label": "", "metadata": {}, "score": "51.63634"}
{"text": "There is good evidence that comorbid conditions , particularly recent surgery or trauma , are very important risk factors for heparin - induced bleeding .26 , 102 , 125 This association was demonstrated in the study by Hull and associates 102 in patients with proximal vein thrombosis .", "label": "", "metadata": {}, "score": "51.65763"}
{"text": "Simonneau , G , Charbonnier , B , Decousus , H , et al Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis .", "label": "", "metadata": {}, "score": "51.66953"}
{"text": "Simonneau , G , Charbonnier , B , Decousus , H , et al Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis .", "label": "", "metadata": {}, "score": "51.66953"}
{"text": "Antman , EM , McCabe , CH , Gurfinkel , EP , et al Enoxaparin prevents death and cardiac ischemic events in unstable angina / non Q wave myocardial infarction : results of the Thrombolysis In Myocardial Infarction ( TIMI )", "label": "", "metadata": {}, "score": "51.68241"}
{"text": "Antman , EM , McCabe , CH , Gurfinkel , EP , et al Enoxaparin prevents death and cardiac ischemic events in unstable angina / non Q wave myocardial infarction : results of the Thrombolysis In Myocardial Infarction ( TIMI )", "label": "", "metadata": {}, "score": "51.68241"}
{"text": "Heparin was continued for 48 to 72 hours with infusion adjusted to maintain aPTT at 50 - 75 seconds .The use of GP IIb / IIIa inhibitors was discouraged for the first 24 hours following randomization .", "label": "", "metadata": {}, "score": "51.75836"}
{"text": "Risk profile and benefits from Gp IIb - IIIa inhibitors among patients with ST - segment elevation myocardial infarction treated with primary angioplasty : a meta - regression analysis of randomized trials .", "label": "", "metadata": {}, "score": "51.79409"}
{"text": "There was no difference in in\u2011hospital major bleeding between the two groups ( 5.6 % vs. 4.4 % for TNKase plus PCI vs. PCI alone , respectively ) .", "label": "", "metadata": {}, "score": "51.807434"}
{"text": "In the following conditions , the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits : .Recent major surgery , e.g. , coronary artery bypass graft , obstetrical delivery , organ biopsy , previous puncture of noncompressible vessels .", "label": "", "metadata": {}, "score": "52.519814"}
{"text": "The results of these trials have shown that heparin administered alone in patients with coronary artery disease ( without concurrent thrombolytic therapy ) is not associated with an increased risk of major bleeding .", "label": "", "metadata": {}, "score": "52.819458"}
{"text": "Levine , MN , Hirsh , J , Gent , M , et al A randomized trial comparing the activated thromboplastin time with the heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin .", "label": "", "metadata": {}, "score": "53.12368"}
{"text": "Levine , MN , Hirsh , J , Gent , M , et al A randomized trial comparing the activated thromboplastin time with the heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin .", "label": "", "metadata": {}, "score": "53.12368"}
{"text": "This study shows that among STEMI patients undergoing primary angioplasty , diabetes is associated with worse long - term mortality , reinfarction , and in - stent thrombosis , even with DES implantation , which was able to overcome the known deleterious effect of diabetes on TVR .", "label": "", "metadata": {}, "score": "53.238636"}
{"text": "Models have been developed for estimating the risk for major bleeding during oral anticoagulant therapy .16 , 24 , 27 - 28 , 30 , 38 , 47 Such prediction rules can be useful in clinical practice because although physicians ' estimates of risk for anticoagulant - related bleeding are reasonably accurate during hospitalization , they are inaccurate during long - term outpatient therapy .", "label": "", "metadata": {}, "score": "53.445114"}
{"text": "Andersson , G , Fagrell , B , Holmgren , K , et al Subcutaneous administration of heparin : a randomized comparison with intravenous administration of heparin to patients with deep vein thrombosis .", "label": "", "metadata": {}, "score": "53.60328"}
{"text": "Andersson , G , Fagrell , B , Holmgren , K , et al Subcutaneous administration of heparin : a randomized comparison with intravenous administration of heparin to patients with deep vein thrombosis .", "label": "", "metadata": {}, "score": "53.60328"}
{"text": "These data and results of meta - analyses 111 - 112 support the inference that LMW heparin does not result in an increased risk of major bleeding compared with unfractionated heparin .", "label": "", "metadata": {}, "score": "53.823654"}
{"text": "In terms of treatment decision making for anticoagulant therapy , bleeding risk can not be considered alone , ie , the potential decrease in thromboembolism must be balanced against the potential increased bleeding risk .", "label": "", "metadata": {}, "score": "53.89299"}
{"text": "We present a patient with acute ischaemic stroke who developed a transient left ventricular apical thrombus after systemic thrombolysis .Case presentation .A 61-year - old man was admitted to the Emergency Department immediately after he experienced global aphasia and right - sided hemiparesis .", "label": "", "metadata": {}, "score": "54.071274"}
{"text": "While DS between 50 and 70 percent has been termed an \" intermediate stenosis , \" the clinical outcome of PCI based on the angiographic criteria of 50 percent or 70 percent has never been studied .", "label": "", "metadata": {}, "score": "54.1989"}
{"text": "These hemostatic changes might contribute to severe complications of rtPA treatment such as vessel reocclusion or recurrent stroke .Therefore , an adjuvant anticoagulation with heparin is performed to prevent reocclusion in myocardial infarction [ 5 ] and after intra - arterial thrombolysis of the basilar artery [ 6 ] .", "label": "", "metadata": {}, "score": "54.24855"}
{"text": "Rates of in - hospital procedures , including percutaneous transluminal coronary angioplasty ( PTCA ) , stent placement , intra - aortic balloon pump ( IABP ) use , and coronary artery bypass graft ( CABG ) surgery , were similar between the TNKase and Activase \u00ae ( Alteplase ) groups .", "label": "", "metadata": {}, "score": "54.29137"}
{"text": "Bleeding is the major complication of anticoagulant therapy .The criteria for defining the severity of bleeding varied considerably between studies , accounting in part for the variation in the rates of bleeding reported .", "label": "", "metadata": {}, "score": "54.58387"}
{"text": "However , concerns have emerged on the potential higher risk of stent thrombosis and death with DES ( 20 , 21 ) , which might be even more pronounced among STEMI patients ( 22 , 23 ) .", "label": "", "metadata": {}, "score": "54.593147"}
{"text": "20 , 38 In contrast , peptic ulcer disease alone , without past bleeding , has not been associated with an increased risk of bleeding .", "label": "", "metadata": {}, "score": "54.638462"}
{"text": "Fiessinger , JN , Lopez - Fernandez , M , Gatterer , E , et al One daily subcutaneous dalteparin , a low molecular weight heparin , for the initial treatment of acute deep vein thrombosis .", "label": "", "metadata": {}, "score": "54.659767"}
{"text": "Fiessinger , JN , Lopez - Fernandez , M , Gatterer , E , et al One daily subcutaneous dalteparin , a low molecular weight heparin , for the initial treatment of acute deep vein thrombosis .", "label": "", "metadata": {}, "score": "54.659767"}
{"text": "In a seventh study , , 6 two intensities of oral anticoagulation were compared following initial heparin therapy ( Table 4 ) .A higher intensity of oral anticoagulation ( ie , INR 2.6 to 4.4 ) was evaluated in the earlier studies , 95 - 97 than in the more recent trials ( ie , INR 2.0 to 3.0 ) .", "label": "", "metadata": {}, "score": "55.001698"}
{"text": "Agnelli , G , Prandoni , P , Santamaria , MG , et al Three months compared with one year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis : the Warfarin Optimal Duration Italian Trial ( WODIT ) [ abstract].", "label": "", "metadata": {}, "score": "55.01455"}
{"text": "Agnelli , G , Prandoni , P , Santamaria , MG , et al Three months compared with one year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis : the Warfarin Optimal Duration Italian Trial ( WODIT ) [ abstract].", "label": "", "metadata": {}, "score": "55.01455"}
{"text": "In 99 of 104 patients treated with Tenecteplase , mean plasma clearance ranged from 99 to 119 mL / min .The initial volume of distribution is weight related and approximates plasma volume .", "label": "", "metadata": {}, "score": "55.350025"}
{"text": "A subanalysis of the PASEO trial showed that at 5-year follow - up , diabetes was associated with a significantly worse outcome with both DES and BMS ( 36 , 37 ) .", "label": "", "metadata": {}, "score": "55.484116"}
{"text": "These events include cardiogenic shock , arrhythmias , atrioventricular block , pulmonary edema , heart failure , cardiac arrest , recurrent myocardial ischemia , myocardial reinfarction , myocardial rupture , cardiac tamponade , pericarditis , pericardial effusion , mitral regurgitation , thrombosis , embolism , and electromechanical dissociation .", "label": "", "metadata": {}, "score": "55.48471"}
{"text": "These included the type of LMW heparin , whether or not the patient received some anticoagulation before enrollment in the trial , and whether treatment was given on an inpatient or outpatient basis .", "label": "", "metadata": {}, "score": "55.51474"}
{"text": "A CT - scan detected no pulmonary embolism , but massive bilateral pleural effusion .TTE revealed an apical thrombus measuring 2.0 \u00d7 2.0 cm in the left ventricle ( figure 1 ) with left ventricular ejection fraction reduced to 20 % .", "label": "", "metadata": {}, "score": "55.864635"}
{"text": "( % ) unless otherwise indicated .Atrial Fibrillation Investigators .Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation : analysis of pooled data from five randomized controlled trials .", "label": "", "metadata": {}, "score": "56.05802"}
{"text": "Coronary thrombolysis may result in arrhythmias associated with reperfusion .These arrhythmias ( such as sinus bradycardia , accelerated idioventricular rhythm , ventricular premature depolarizations , ventricular tachycardia ) are not different from those often seen in the ordinary course of acute myocardial infarction and may be managed with standard anti\u2011arrhythmic measures .", "label": "", "metadata": {}, "score": "56.097492"}
{"text": "Several studies have demonstrated that hyperglycemia at admission , even independently from the presence of diabetes ( stress hyperglycemia ) , is associated with larger infarct size and higher mortality in patients with STEMI ( 24 - 28 ) .", "label": "", "metadata": {}, "score": "56.16452"}
{"text": "Rates of intracranial hemorrhage during long - term oral anticoagulant therapy are presented in Table 5 .In a case - control study , the risk of intracerebral hemorrhage doubled for each increase of approximately 1 in the INR .", "label": "", "metadata": {}, "score": "56.167786"}
{"text": "The corresponding numbers of major extracranial bleeds were 7 , 8 , 5 , and 1 , respectively .For an individual patient , the cumulative risk of bleeding is directly related to the length of anticoagulant therapy .", "label": "", "metadata": {}, "score": "56.321083"}
{"text": "Paganelli F , Alessi MC , Morange P , Maixent JM , Levy S , Vague IJ : Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt - PA as compared to streptokinase and patency of infarct related coronary artery .", "label": "", "metadata": {}, "score": "56.3732"}
{"text": "In patients with acute myocardial infarction ( AMI ) , TNKase administered as a single bolus exhibits a biphasic disposition from the plasma .Tenecteplase was cleared from the plasma with an initial half - life of 20 to 24 minutes .", "label": "", "metadata": {}, "score": "56.39132"}
{"text": "Altman et al 58 compared two different doses of aspirin ( 100 mg / d vs 650 mg / d ) in patients receiving acenocoumarol at an INR of 2.0 to 3.0 .", "label": "", "metadata": {}, "score": "56.400307"}
{"text": "These results were confirmed in patients receiving BMS or DES , except for TVR , there being no difference observed between diabetic and nondiabetic patients treated with DES .", "label": "", "metadata": {}, "score": "56.40706"}
{"text": "Monreal , M , Lafoz , E , Olive , A , et al Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin ( Fragmin ) in patients with venous thromboembolism and contraindications to coumarin .", "label": "", "metadata": {}, "score": "56.450176"}
{"text": "Monreal , M , Lafoz , E , Olive , A , et al Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin ( Fragmin ) in patients with venous thromboembolism and contraindications to coumarin .", "label": "", "metadata": {}, "score": "56.450176"}
{"text": "PubMed .Circulation 2003 , 108 : 1278 - 1290 .View Article PubMed .Greaves SC , Zhi G , Lee RT , Solomon SD , MacFadyen J , Rapaport E , Menapace FJ , Rouleau JL , Pfeffer MA : Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction .", "label": "", "metadata": {}, "score": "56.466022"}
{"text": "Acar , J , Iung , B , Boissel , JP , et al AREVA : multicenter randomized comparison of low dose versus standard dose anticoagulation in patients with mechanical prosthetic heart valves .", "label": "", "metadata": {}, "score": "56.583168"}
{"text": "Acar , J , Iung , B , Boissel , JP , et al AREVA : multicenter randomized comparison of low dose versus standard dose anticoagulation in patients with mechanical prosthetic heart valves .", "label": "", "metadata": {}, "score": "56.583168"}
{"text": "Precautions .General .Standard management of myocardial infarction should be implemented concomitantly with TNKase treatment .Arterial and venous punctures should be minimized .Noncompressible arterial puncture must be avoided and internal jugular and subclavian venous punctures should be avoided to minimize bleeding from the noncompressible sites .", "label": "", "metadata": {}, "score": "56.8592"}
{"text": "TNKase therapy in patients with acute myocardial infarction is contraindicated in the following situations because of an increased risk of bleeding ( see WARNINGS ): .", "label": "", "metadata": {}, "score": "56.861336"}
{"text": "Recent gastrointestinal or genitourinary bleeding .High likelihood of left heart thrombus , e.g. , mitral stenosis with atrial fibrillation .Subacute bacterial endocarditis .Hemostatic defects , including those secondary to severe hepatic or renal disease .", "label": "", "metadata": {}, "score": "56.89353"}
{"text": "The bleeding incidence increased by a factor of 1.4 for each 0.5-U increase of the INR .In our previous reviews of bleeding rates in patients receiving long - term oral anticoagulant therapy for prosthetic heart valves , a number of trials that were reported in the 1970s and 1980s were considered .", "label": "", "metadata": {}, "score": "56.90023"}
{"text": "Circulation 2004 ; 109 : 1704 - 1706 pmid : 15066943 .Angiographic findings , time course of regional and global left ventricular function , and clinical outcome in diabetic patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty .", "label": "", "metadata": {}, "score": "57.022507"}
{"text": "Pengo , V , Barbero , F , Banzato , A , et al A comparison of a moderate with moderate - high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses .", "label": "", "metadata": {}, "score": "57.041862"}
{"text": "Pengo , V , Barbero , F , Banzato , A , et al A comparison of a moderate with moderate - high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses .", "label": "", "metadata": {}, "score": "57.041862"}
{"text": "Percutaneous coronary intervention - related time delay , patient 's risk profile , and survival benefits of primary angioplasty vs lytic therapy in ST - segment elevation myocardial infarction .", "label": "", "metadata": {}, "score": "57.062695"}
{"text": "Background .Recombinant tissue plasminogen activator ( rtPA ) is an approved treatment option for acute ischemic stroke within three hours of symptoms onset .It is well known that reperfusion of ischaemic brain tissue , when performed in a timely manner , improves clinical outcome [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "57.073273"}
{"text": "Affiliated with .Abstract .Background .Thrombolysis with recombinant tissue plasminogen activator ( rtPA ) is an established treatment in acute stroke .To prevent rethrombosis after rtPA therapy , secondary anticoagulation with heparin is commonly performed .", "label": "", "metadata": {}, "score": "57.091057"}
{"text": "Lopaciuk , S , Meissner , AJ , Filipecki , S , et al Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis : a Polish multicenter trial .", "label": "", "metadata": {}, "score": "57.130295"}
{"text": "Lopaciuk , S , Meissner , AJ , Filipecki , S , et al Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis : a Polish multicenter trial .", "label": "", "metadata": {}, "score": "57.130295"}
{"text": "This difference was statistically significant .The Coumadin - Aspirin Reinfarction Study 42 compared long - term treatment using fixed low doses of warfarin ( 1 mg or 3 mg ) combined with aspirin , 80 mg , to treatment with aspirin alone ( 160 mg ) using a randomized double - blind study design .", "label": "", "metadata": {}, "score": "57.17393"}
{"text": "The rate of intracranial and spinal bleeding was 0.57%/yr , and the rate of major extracranial bleeding was 2.1%/yr .The efficacy of warfarin in preventing stroke in patients with nonvalvular atrial fibrillation has been consistently demonstrated in a number of randomized clinical trials and in meta - analyses .", "label": "", "metadata": {}, "score": "57.20028"}
{"text": "Bleeding occurred in seven adjusted - dose patients compared with none in the fixed - dose group .Subgroup analysis of randomized trials and prospective cohort studies provide suggestive evidence for an association between the incidence of bleeding and the anticoagulant response .", "label": "", "metadata": {}, "score": "57.206253"}
{"text": "REFERENCES .ASSENT-2 Investigators .Single - bolus tenecteplase compared with front - loaded alteplase in acute myocardial infarction : the ASSENT-2 double - blind randomised trial .", "label": "", "metadata": {}, "score": "57.2065"}
{"text": "Diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions .Septic thrombophlebitis or occluded AV cannula at seriously infected site .Patients currently receiving oral anticoagulants , e.g. , warfarin sodium .", "label": "", "metadata": {}, "score": "57.327576"}
{"text": "To our knowledge , there have been no randomized trials in patients with established venous thromboembolism directly comparing different doses of heparin .In a study 154 evaluating prophylaxis in patients with recent - onset traumatic spinal cord injuries , the incidence of bleeding was significantly greater in patients randomized to receive heparin adjusted to maintain the APTT at 1.5 times control than compared with heparin , 5,000 U bid .", "label": "", "metadata": {}, "score": "57.455597"}
{"text": "A number of studies 17 - 31 have found that the frequency of bleeding during warfarin therapy is higher in older patients , although other studies 16 , 32 - 36 have not .", "label": "", "metadata": {}, "score": "57.49848"}
{"text": "Cannon CP , Gibson CM , McCabe CH , Adgey AAJ , Schweiger MJ , Sequeira RF , et al .TNK - tissue plasminogen activator compared with front - loaded alteplase in acute myocardial infarction .", "label": "", "metadata": {}, "score": "57.559464"}
{"text": "Circulation1999;100,1593 - 1601 .Data are presented as No .( % ) unless otherwise indicated .Atrial Fibrillation Investigators .Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation : analysis of pooled data from five randomized controlled trials .", "label": "", "metadata": {}, "score": "57.65555"}
{"text": "However , although diabetes was associated with a significantly higher rate of TVR among patients treated with DES , it did increase TVR among patients treated with DES .", "label": "", "metadata": {}, "score": "57.67132"}
{"text": "Use with Percutaneous Coronary Intervention ( PCI ) .In patients with large ST segment elevation myocardial infarction , physicians should choose either thrombolysis or PCI as the primary treatment strategy for reperfusion .", "label": "", "metadata": {}, "score": "57.785007"}
{"text": "The total rates of major bleeding were between 0 % and 6.8 % , and the addition of aspirin to warfarin increased the risk of minor bleeding .", "label": "", "metadata": {}, "score": "57.99124"}
{"text": "The optimal time - point of anticoagulation after systemic thrombolysis is unclear due to a lack of evidence .In accordance with the NINDS - protocol anticoagulation is interdicted within 24 hours after thrombolysis [ 1 ] .", "label": "", "metadata": {}, "score": "58.094814"}
{"text": "View Article PubMed .Kuker W , Friese S , Vogel W , Schmidt F , Weller M : Incomplete resolution of basilar artery occlusion after intra - arterial thrombolysis : abciximab and heparin prevent early rethrombosis .", "label": "", "metadata": {}, "score": "58.133003"}
{"text": "Impact of diabetes on survival in patients with ST - segment elevation myocardial infarction treated by primary angioplasty : insights from the POLISH STEMI registry .", "label": "", "metadata": {}, "score": "58.160625"}
{"text": "Coronary angiography was not performed , considering the cerebral state of the patient and the observation that repeated ECGs were normal and cardiac enzymes not elevated .", "label": "", "metadata": {}, "score": "58.382595"}
{"text": "Gould , MK , Dembitzer , A , Doyle , R , et al Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis : a meta - analysis of randomized controlled trials .", "label": "", "metadata": {}, "score": "58.451378"}
{"text": "Gould , MK , Dembitzer , A , Doyle , R , et al Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis : a meta - analysis of randomized controlled trials .", "label": "", "metadata": {}, "score": "58.451378"}
{"text": "Davis , FB , Estruch , MT , Samson - Corvera , EB , et al Management of anticoagulation in outpatients : experience with an anticoagulation service in a municipal hospital setting .", "label": "", "metadata": {}, "score": "58.528645"}
{"text": "Davis , FB , Estruch , MT , Samson - Corvera , EB , et al Management of anticoagulation in outpatients : experience with an anticoagulation service in a municipal hospital setting .", "label": "", "metadata": {}, "score": "58.528645"}
{"text": "View Article .JAMA 1995 , 274 : 1017 - 1025 .View Article PubMed .Fassbender K , Dempfle CE , Mielke O , Schwartz A , Daffertshofer M , Eschenfelder C , Dollman M , Hennerici M : Changes in Coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant plasminogen activator .", "label": "", "metadata": {}, "score": "58.53733"}
{"text": "Few data have been reported regarding diabetic patients with STEMI in the era of DES .A recent individual patient data meta - analysis showed that among STEMI diabetic patients undergoing primary angioplasty , the use of DES was safe and associated with a significant reduction in TVR at 1-year follow - up .", "label": "", "metadata": {}, "score": "58.694553"}
{"text": "PubMed .Frostfeldt G , Gustavsson G , Lindahl B , Nygren A , Wallentin L : Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction .", "label": "", "metadata": {}, "score": "58.699055"}
{"text": "Acute hyperglycemia increases intercellular adhesion molecule-1 levels ( 29 ) , which could augment plugging of leukocytes in the capillaries ( 30 ) .Hyperglycemia also may augment thrombus formation .", "label": "", "metadata": {}, "score": "58.753914"}
{"text": "View Article PubMed .Wardlaw JM , Zoppo G , Yamaguchi T , Berge E : Thrombolysis for acute ischaemic stroke .Cochrane Databaes Syst Rev 2003 , : CDOOO213 .", "label": "", "metadata": {}, "score": "58.822876"}
{"text": "Bar graphs show time distribution of stent thrombosis in overall population .BMS Kaplan - Meier survival curves show the impact of diabetes on event - free survival from stent thrombosis in overall population ( A ) , in patients with BMS ( B ) , and in patients with DES ( C ) .", "label": "", "metadata": {}, "score": "58.85427"}
{"text": "The annual bleeding rates ( percentage per year ) were reported in several trials ( Table 1 ) .These rates of major bleeding were between 1.2%/yr and 5.6%/yr .", "label": "", "metadata": {}, "score": "58.956604"}
{"text": "Siragusa , S , Cosmi , B , Piovella , F , et al Low - molecular - weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism : results of a meta - analysis .", "label": "", "metadata": {}, "score": "59.18553"}
{"text": "Siragusa , S , Cosmi , B , Piovella , F , et al Low - molecular - weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism : results of a meta - analysis .", "label": "", "metadata": {}, "score": "59.18553"}
{"text": "Impact of admission hyperglycemia and diabetes mellitus on short- and long - term mortality after acute myocardial infarction in the coronary intervention era .Am J Cardiol 2007 ; 99 : 1674 - 1679 pmid : 17560874 .", "label": "", "metadata": {}, "score": "59.32215"}
{"text": "The major determinants of oral anticoagulant - induced bleeding are the intensity of the anticoagulant effect , patient characteristics , the concomitant use of drugs that interfere with hemostasis , and the length of therapy .", "label": "", "metadata": {}, "score": "59.393364"}
{"text": "The angiographic results from TIMI 10B and the safety data from ASSENT-1 , an additional uncontrolled safety study of 3,235 TNKase - treated patients , provided the framework to develop a weight - tiered TNKase dose regimen .", "label": "", "metadata": {}, "score": "59.518974"}
{"text": "International Stroke Trial Collaborative Group .The International Stroke Trial ( IST ) : a randomized trial of aspirin , subcutaneous heparin , both or neither among 19,435 patients with acute ischemic stroke .", "label": "", "metadata": {}, "score": "59.542976"}
{"text": "International Stroke Trial Collaborative Group .The International Stroke Trial ( IST ) : a randomized trial of aspirin , subcutaneous heparin , both or neither among 19,435 patients with acute ischemic stroke .", "label": "", "metadata": {}, "score": "59.542976"}
{"text": "Clinical features of cholesterol embolism may include livedo reticularis , \" purple toe \" syndrome , acute renal failure , gangrenous digits , hypertension , pancreatitis , myocardial infarction , cerebral infarction , spinal cord infarction , retinal artery occlusion , bowel infarction , and rhabdomyolysis .", "label": "", "metadata": {}, "score": "59.906254"}
{"text": "Stroke 2005 , 36 : 916 - 921 .View Article PubMed .Schenkel J , Weimar C , Knoll T , Haberl RL , Busse O , Hamann GF , Koennecke HC , Diener HC : R1-Systemic Thrombolysis in German Stroke Units .", "label": "", "metadata": {}, "score": "59.93457"}
{"text": "Diabetes 1993 ; 42 : 1017 - 1025 pmid : 8513969 .Benefits of drug - eluting stents as compared to bare metal stent in ST - segment elevation myocardial infarction : four year results of the PaclitAxel or Sirolimus - Eluting stent vs bare metal stent in primary angiOplasty ( PASEO ) randomized trial .", "label": "", "metadata": {}, "score": "60.11742"}
{"text": "RESULTS .Patient population .Our population is represented by 6,298 STEMI patients .Diabetes was observed in 972 ( 15.4 % ) patients .No difference was observed in terms of angiographic and procedural characteristics .", "label": "", "metadata": {}, "score": "60.126163"}
{"text": "113 - 115 Two additional randomized trials have evaluated long - term oral anticoagulation for the prevention of recurrent venous thromboembolism following an acute episode .", "label": "", "metadata": {}, "score": "60.268517"}
{"text": "This is first large report on the impact of diabetes on long - term outcome of STEMI patients undergoing primary angioplasty with BMS or DES .", "label": "", "metadata": {}, "score": "60.315125"}
{"text": "Although the concomitant use of aspirin is associated with heparin - induced bleeding , this combination is used frequently in the initial treatment of acute coronary artery syndromes without serious bleeding .", "label": "", "metadata": {}, "score": "60.353096"}
{"text": "rt - PA has a short biological half - life of 8 - 12 minutes but alters the physiological balance between coagulation and anticoagulation for a longer time period [ 11 ] .", "label": "", "metadata": {}, "score": "60.37245"}
{"text": "Patients were to be excluded from the trial if they received GP IIb / IIIa inhibitors within the previous 12 hours .TNKase was dosed using actual or estimated weight in a weight - tiered fashion as described in DOSAGE AND ADMINISTRATION .", "label": "", "metadata": {}, "score": "60.411808"}
{"text": "Transthoracic echocardiography ( TTE ) 12 hours after admission showed slightly reduced left ventricular ejection fraction ( LVEF ) but was otherwise normal .48 hours later the patient suddenly deteriorated with clinical signs of dyspnea and tachycardia .", "label": "", "metadata": {}, "score": "60.412666"}
{"text": "Major bleeding rates , defined as bleeding requiring blood transfusion or leading to hemodynamic compromise , were 3.1 % in patients under the age of 65 , 6.4 % in patients between the ages of 65 and 74 , and 7.7 % in patients age 75 and over .", "label": "", "metadata": {}, "score": "60.4667"}
{"text": "View Article PubMed .Vaitkus PT , Barnathan ES : Embolic potential , prevention and management of mural thrombus complicating anterior myocardial infarction : a meta - analysis .", "label": "", "metadata": {}, "score": "60.613586"}
{"text": "Although many other patient characteristics have been associated with bleeding during warfarin therapy , the data supporting these findings are not compelling .For example , some studies 16 , 21 - 22 , 24 , 27 noted an increased frequency of bleeding among women treated with warfarin , but several others 21 , 23 , 26 , 33 - 34 have not .", "label": "", "metadata": {}, "score": "60.75885"}
{"text": "This difference was statistically significant .In the trial conducted by Acar et al , 65 380 patients were randomized to treatment with acenocoumarol at a targeted INR of 2.0 to 3.0 or the same medication at a targeted INR of 3.0 to 4.5 .", "label": "", "metadata": {}, "score": "60.786705"}
{"text": "Chesebro , JH , Fuster , V , Elveback , LR , et al Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement : danger of aspirin compared with dipyridamole .", "label": "", "metadata": {}, "score": "61.069057"}
{"text": "Chesebro , JH , Fuster , V , Elveback , LR , et al Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement : danger of aspirin compared with dipyridamole .", "label": "", "metadata": {}, "score": "61.069057"}
{"text": "Glycoprotein IIb - IIIa inhibitors were equally administrated in both groups ( 71.9 % vs. 69.9 % ) , as much as statin therapy at discharge ( 96.5 % vs. 95.1 % ) .", "label": "", "metadata": {}, "score": "61.130096"}
{"text": "Petersen , P , Boysan , G , Godtfredsen , J , et al Placebo - controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation : the Copenhagen AFASAK study .", "label": "", "metadata": {}, "score": "61.507492"}
{"text": "Petersen , P , Boysan , G , Godtfredsen , J , et al Placebo - controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation : the Copenhagen AFASAK study .", "label": "", "metadata": {}, "score": "61.507492"}
{"text": "This fibrin specificity decreases systemic activation of plasminogen and the resulting degradation of circulating fibrinogen as compared to a molecule lacking this property .Following administration of 30 , 40 , or 50 mg of TNKase , there are decreases in circulating fibrinogen ( 4%-15 % ) and plasminogen ( 11%-24 % ) .", "label": "", "metadata": {}, "score": "62.0458"}
{"text": "Five patients in the warfarin group ( 0.8 % ) had intracranial hemorrhages , and three of these were fatal .Eight warfarin - treated patients ( 1.3 % ) experienced major extracranial bleeds .", "label": "", "metadata": {}, "score": "62.213966"}
{"text": "The median INR values 4 weeks and 6 months after beginning treatment were 1.3 and 1.2 , respectively , for patients given warfarin , 3 mg , and 1.0 at both times for patients given either warfarin , 1 mg , or aspirin , 160 mg , alone .", "label": "", "metadata": {}, "score": "62.238846"}
{"text": "Am Heart J 2008 ; 155 : 284 - 289 pmid : 18215598 .Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST - segment elevation acute myocardial infarction with versus without diabetes mellitus ( from the EMERALD Trial ) .", "label": "", "metadata": {}, "score": "62.287285"}
{"text": "Anand and Yusuf 93 have conducted a meta - analysis of trials evaluating oral anticoagulant therapy in patients with coronary artery disease .Trials were stratified based on the intensity of oral anticoagulant therapy and on the use of aspirin .", "label": "", "metadata": {}, "score": "62.28794"}
{"text": "This difference was not statistically significant .In a trial conducted by Pengo and colleagues , 66 205 patients were randomized to treatment with either warfarin or acenocoumarol at a targeted INR of 2.5 to 3.5 or the same medications at a targeted INR of 3.5 to 4.5 .", "label": "", "metadata": {}, "score": "62.296024"}
{"text": "Bleeding .The most common complication encountered during TNKase therapy is bleeding .The type of bleeding associated with thrombolytic therapy can be divided into two broad categories : .", "label": "", "metadata": {}, "score": "62.334557"}
{"text": "Prevalence , predictors , and outcomes of premature discontinuation of thienopyridine therapy after drug - eluting stent placement : results from the PREMIER registry .Circulation 2006 ; 113 : 2803 - 2809 pmid : 16769908 .", "label": "", "metadata": {}, "score": "62.391827"}
{"text": "Gullov , AL , Koefoed , BG , Petersen , P , et al Fixed minidose warfarin and aspirin alone and in combination vs adjusted - dose warfarin for stroke prevention in atrial fibrillation : Second Copenhagen Atrial Fibrillation , Aspirin , and Anticoagulation Study .", "label": "", "metadata": {}, "score": "62.495346"}
{"text": "Gullov , AL , Koefoed , BG , Petersen , P , et al Fixed minidose warfarin and aspirin alone and in combination vs adjusted - dose warfarin for stroke prevention in atrial fibrillation : Second Copenhagen Atrial Fibrillation , Aspirin , and Anticoagulation Study .", "label": "", "metadata": {}, "score": "62.495346"}
{"text": "Adjusted - dose warfarin versus low - intensity , fixed - dose warfarin plus aspirin for high - risk patients with atrial fibrillation : Stroke Prevention in Atrial Fibrillation III randomised clinical trial .", "label": "", "metadata": {}, "score": "62.78544"}
{"text": "Adjusted - dose warfarin versus low - intensity , fixed - dose warfarin plus aspirin for high - risk patients with atrial fibrillation : Stroke Prevention in Atrial Fibrillation III randomised clinical trial .", "label": "", "metadata": {}, "score": "62.78544"}
{"text": "157 The association of aspirin ingestion with heparin - induced bleeding was confirmed by Sethi and associates 158 in their study in patients undergoing aortocoronary bypass surgery .", "label": "", "metadata": {}, "score": "62.869946"}
{"text": "Closed echocardiographic monitoring in stroke patients treated with systemic thrombolysis might be useful for early detection of the described potential cardiac complications especially because repeated measurement of ECG and cardiac enzymes alone might fail .", "label": "", "metadata": {}, "score": "62.916172"}
{"text": "A cranial CT - scan showed no early signs of cerebral infarct and no intracranial bleeding .Atrial fibrillation was recognised on the initial ECG and an cerebral infarct of cardiac embolic origin was assumed .", "label": "", "metadata": {}, "score": "62.985973"}
{"text": "Adverse Reactions .Bleeding .The most frequent adverse reaction associated with TNKase is bleeding ( see WARNINGS ) .Should serious bleeding occur , concomitant heparin and antiplatelet therapy should be discontinued .", "label": "", "metadata": {}, "score": "63.207893"}
{"text": "Kilic E , B\u00e4hr M , Hermann DM : Effect of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice .Role of hemodynamic alterations .", "label": "", "metadata": {}, "score": "63.526108"}
{"text": "The Stroke Prevention in Reversible Ischemia Trial ( SPIRIT )Study Group .A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin .", "label": "", "metadata": {}, "score": "63.58278"}
{"text": "The Stroke Prevention in Reversible Ischemia Trial ( SPIRIT )Study Group .A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin .", "label": "", "metadata": {}, "score": "63.58278"}
{"text": "Limitations .Our patients were enrolled in randomized trials , and few patients had cardiogenic shock .Thus , the conclusion of this meta - analysis can not be extended to all patients undergoing primary PCI for STEMI .", "label": "", "metadata": {}, "score": "63.796555"}
{"text": "TNKase has been shown to elicit maternal and embryo toxicity in rabbits given multiple IV administrations .In rabbits administered 0.5 , 1.5 , and 5.0 mg / kg / day , vaginal hemorrhage resulted in maternal deaths .", "label": "", "metadata": {}, "score": "64.033165"}
{"text": "Transthoracic echocardiography ( TTE ) performed 12 hours after initiation of thrombolytic therapy revealed a moderately reduced left ventricular systolic function ( ejection fraction : 41 % ) , left ventricular regional dyssynergy , and no intracardiac thrombus .", "label": "", "metadata": {}, "score": "64.07761"}
{"text": "Diabetes mellitus is associated with distal embolization , impaired myocardial perfusion , and higher mortality in patients with ST - segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb - IIIa inhibitors .", "label": "", "metadata": {}, "score": "64.13323"}
{"text": "Cerebral hemorrhage was more common in patients who had been treated with anticoagulants ( 17 cases ; 1 % ) , 8 of which were fatal , compared with 2 cases in placebo - treated patients , none of which were fatal .", "label": "", "metadata": {}, "score": "64.173874"}
{"text": "Impact of diabetes on long - term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb - IIIa inhibitors and BMS or DES .J Thromb Thrombolysis 2010 ; 30 : 133 - 141 pmid : 19921102 TNKase .", "label": "", "metadata": {}, "score": "64.285355"}
{"text": "Intramuscular injections and nonessential handling of the patient should be avoided for the first few hours following treatment with TNKase .Venipunctures should be performed and monitored carefully .", "label": "", "metadata": {}, "score": "64.50877"}
{"text": "In three trials , different intensities of oral anticoagulants were compared . , 8 , 65 - 66 Saour et al 8 randomized patients to either moderate - intensity warfarin therapy ( targeted INR 2.65 ) or very - high - intensity warfarin therapy ( targeted INR , 9.0 ) .", "label": "", "metadata": {}, "score": "64.51475"}
{"text": "Nausea and/or vomiting , hypotension , and fever have also been reported .Reconstitution .NOTE :Read all instructions completely before beginning reconstitution and administration .", "label": "", "metadata": {}, "score": "64.6035"}
{"text": "The major determinants of oral anticoagulant - induced bleeding are the intensity of the anticoagulant effect , underlying patient characteristics , and the length of therapy .", "label": "", "metadata": {}, "score": "64.61383"}
{"text": "View Article PubMed .Maki A , Shirato C , Ohguchi M , Aoki N , Ochiai I , Ishikawa K : Mechanism of re - thrombosis after thrombolytic therapy : angiographic findings and investigation of the coagulation system in dogs .", "label": "", "metadata": {}, "score": "64.85148"}
{"text": "The Trial of ORG10172 in Acute Stroke Treatment study 143 randomized 1,281 patients with acute ischemic stroke to a 7-day course of IV danaparoid sodium or placebo treatment .", "label": "", "metadata": {}, "score": "64.86136"}
{"text": "Total outlays ............................................. 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 .Conservative approach to revascularization is safe .Date : .A new study shows that a conservative approach to revascularization for patients with intermediate coronary lesions determined by angiographic diameter stenosis is safe and non - inferior to an aggressive approach .", "label": "", "metadata": {}, "score": "64.952194"}
{"text": "The differences in event rates between groups during the follow - up period were assessed by the Kaplan - Meier method using the log - rank test .", "label": "", "metadata": {}, "score": "65.01503"}
{"text": "This difference was statistically significant .In a double - blind trial , Turpie et al 63 compared warfarin ( INR 3.0 to 4.5 ) with warfarin plus aspirin , 100 mg .", "label": "", "metadata": {}, "score": "65.50447"}
{"text": "Non - intracranial major bleeding and the need for blood transfusions were lower in patients treated with TNKase .Types of major bleeding reported in 1 % or more of the patients were hematoma ( 1.7 % ) and gastrointestinal tract ( 1 % ) .", "label": "", "metadata": {}, "score": "65.69789"}
{"text": "Morocutti , C , Amabile , G , Fattapposta , F , et al Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation : SIFA ( Studio Italiano Fibrillazione Atriale ) Investigators .", "label": "", "metadata": {}, "score": "66.227425"}
{"text": "Morocutti , C , Amabile , G , Fattapposta , F , et al Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation : SIFA ( Studio Italiano Fibrillazione Atriale ) Investigators .", "label": "", "metadata": {}, "score": "66.227425"}
{"text": "Dextrose - containing lines should be flushed with a saline - containing solution prior to and following single bolus administration of TNKase .Reconstituted TNKase should be administered as a single IV bolus over 5 seconds .", "label": "", "metadata": {}, "score": "66.2716"}
{"text": "Robert , et al .: Evidence of stunned myocardium in humans : a 2001 update .Coron Artery Dis 2001 , 12 : 349 - 356 .", "label": "", "metadata": {}, "score": "66.38818"}
{"text": "- 68 .Fragmin and Fast Revascularization during Instability in Coronary artery disease ( FRISC II ) Investigators .Long term low molecular mass heparin in unstable coronary artery disease : FRISC II prospective randomized multicentre study .", "label": "", "metadata": {}, "score": "66.55867"}
{"text": "- 68 .Fragmin and Fast Revascularization during Instability in Coronary artery disease ( FRISC II ) Investigators .Long term low molecular mass heparin in unstable coronary artery disease : FRISC II prospective randomized multicentre study .", "label": "", "metadata": {}, "score": "66.55867"}
{"text": "This can lead to degradation of fibrinogen in blood samples removed for analysis .Carcinogenesis , Mutagenesis , Impairment of Fertility .Studies in animals have not been performed to evaluate the carcinogenic potential , mutagenicity , or the effect on fertility .", "label": "", "metadata": {}, "score": "66.925934"}
{"text": "DES implantation , however , does mitigate the known deleterious effect of diabetes on TVR after BMS .Primary angioplasty currently represents the best reperfusion therapy for the treatment of ST - segment elevation myocardial infarction ( STEMI )", "label": "", "metadata": {}, "score": "67.03715"}
{"text": "Admission glucose and HbA1c levels that have been shown as major determinants of outcome in STEMI patients were not routinely collected .Data regarding the duration of diabetes and the therapeutic regimen were not available , and the type of diabetes was not uniformly defined among studies ( IDDM / NIDDM in some or any insulin - requiring diabetes in some others ) .", "label": "", "metadata": {}, "score": "67.2853"}
{"text": "Publications Committee for the Trial of ORG10172 in Acute Stroke Treatment ( TOAST )Investigators .Low molecular weight heparinoid , ORG10172 ( Danaparoid ) , and outcome after acute ischemic stroke : a randomized controlled trialJAMA1998;279,1265 - 1272 .", "label": "", "metadata": {}, "score": "67.32743"}
{"text": "Publications Committee for the Trial of ORG10172 in Acute Stroke Treatment ( TOAST )Investigators .Low molecular weight heparinoid , ORG10172 ( Danaparoid ) , and outcome after acute ischemic stroke : a randomized controlled trialJAMA1998;279,1265 - 1272 .", "label": "", "metadata": {}, "score": "67.32743"}
{"text": "A recent study suggested that a microthrombus in the capillaries play a crucial role in the no - reflow phenomenon after STEMI ( 32 ) .", "label": "", "metadata": {}, "score": "67.37715"}
{"text": "Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location .Cholesterol Embolization .Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents ; the true incidence is unknown .", "label": "", "metadata": {}, "score": "67.45441"}
{"text": "However , acute neurogenic myocardial stunning has so far only been reported after subarachnoid hemorrhage [ 17 - 20 ] and in isolated cases of subdural hematoma [ 21 ] and Guillain - Barr\u00e9 syndrome [ 22 ] .", "label": "", "metadata": {}, "score": "67.55677"}
{"text": "TNKase \u00ae ( Tenecteplase ) is indicated for use in the reduction of mortality associated with acute myocardial infarction ( AMI ) .Treatment should be initiated as soon as possible after the onset of AMI symptoms ( see CLINICAL STUDIES ) .", "label": "", "metadata": {}, "score": "67.84908"}
{"text": "16 - 17 This effect is probably attributable to increased frequency and degree of marked elevations in the INR .In many studies , especially those conducted before the era of less intense warfarin therapy , major bleeding was especially frequent in patients with ischemic cerebral vascular disease or venous thromboembolism .", "label": "", "metadata": {}, "score": "67.908676"}
{"text": "This in four months ?Will they be up 18 % , 20 % or more for the year ?Not in TB 's book !", "label": "", "metadata": {}, "score": "68.69293"}
{"text": "Determine the appropriate dose of TNKase ( see Dose Information Table ) and withdraw this volume ( in milliliters ) from the reconstituted vial with the syringe .", "label": "", "metadata": {}, "score": "68.71182"}
{"text": "Heparin was associated with a dose - dependent increase of both intracranial and extracranial bleeding that , at the higher dose , more than offset the antithrombotic benefit .", "label": "", "metadata": {}, "score": "68.83898"}
{"text": "Occult pathologic lesions may also precipitate warfarin - related bleeding .In one study , patients who bled with the prothrombin time ( PT ) in the therapeutic range were more likely to have an underlying pathologic lesion as the cause of bleeding than patients whose bleeding occurred when the PT was elevated above the therapeutic range .", "label": "", "metadata": {}, "score": "68.97001"}
{"text": "Table 1 ASSENT-2 Mortality , Stroke , and Combined Outcome of Death or Stroke Measured at Thirty Days .Rates of mortality and the combined endpoint of death or stroke among pre - specified subgroups , including age , gender , time to treatment , infarct location , and history of previous myocardial infarction , demonstrate consistent relative risks across these subgroups .", "label": "", "metadata": {}, "score": "69.13196"}
{"text": "J Neurol 2003 , 250 : 320 - 324 .View Article PubMed .Determination of etiological , topographic , and radiological outcome factors .Stroke 1998 , 29 : 2529 - 2540 .", "label": "", "metadata": {}, "score": "69.16054"}
{"text": "If the reconstituted TNKase is not used immediately , refrigerate the TNKase vial at 2 - 8 \u00b0 C ( 36 - 46 \u00b0 F ) and use within 8 hours .", "label": "", "metadata": {}, "score": "69.161255"}
{"text": "Department of Neurology , University Hospital Charit\u00e9 .Department of Cardiology , University Hospital Charit\u00e9 .References .The National Institute of Neurological Diseases and Stroke rt - PA Stroke Study Group : Tissue plasminogen activator for ischaemic stroke .", "label": "", "metadata": {}, "score": "69.70949"}
{"text": "OBJECTIVE Diabetes has been shown to be associated with worse survival and repeat target vessel revascularization ( TVR ) after primary angioplasty .The aim of the current study was to evaluate the impact of diabetes on long - term outcome in patients undergoing primary angioplasty treated with bare metal stents ( BMS ) and drug - eluting stents ( DES ) .", "label": "", "metadata": {}, "score": "70.51286"}
{"text": "Renal failure and patient gender have also been implicated as risk factors for heparin - induced bleeding .161 - 162 The reported association with female gender has not been consistent among studies and remains in question .", "label": "", "metadata": {}, "score": "71.58443"}
{"text": "NDC 50242 - 038 - 61 .Stability and Storage .Store lyophilized TNKase at controlled room temperature not to exceed 30 \u00b0 C ( 86 \u00b0 F ) or under refrigeration 2 - 8 \u00b0 C ( 36 - 46 \u00b0 F ) .", "label": "", "metadata": {}, "score": "71.68552"}
{"text": "View Article PubMed .Jain , et al .: Management of patients with stunned myocardium associated with subarachnoid hemorrhage .Am J Neuroradiol 2004 , 25 : 126 - 129 .", "label": "", "metadata": {}, "score": "71.846565"}
{"text": "For these reasons , comparison of the incidence of antibodies to TNKase with the incidence of antibodies to other products may be misleading .Although sustained antibody formation in patients receiving one dose of TNKase has not been documented , readministration should be undertaken with caution .", "label": "", "metadata": {}, "score": "71.95683"}
{"text": "The data reflect the percentage of patients whose test results were considered positive for antibodies to TNKase in a radioimmunoprecipitation assay , and are highly dependent on the sensitivity and specificity of the assay .", "label": "", "metadata": {}, "score": "72.107635"}
{"text": "061009585 ( 2.2- 0.1- ) 061021 442 ( 1.1- 1.8 + ) 111217 J77 0.2- 1.3- .Ephemeris : .P/2006 T1 ( Levy ) .", "label": "", "metadata": {}, "score": "72.14662"}
{"text": "The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators .The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation .", "label": "", "metadata": {}, "score": "72.53766"}
{"text": "The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators .The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation .", "label": "", "metadata": {}, "score": "72.53766"}
{"text": "Advance / Declines were only modestly positive : +1.5x vs +2.6x vs +3.1x vs -2.6x vs +2x vs +2.8x .( compare to +4x , +2.6x , -3.5x , +4.4x , -7.1x ) on NYSE and +1.5x vs +2.8x vs +3x vs -3.5x .", "label": "", "metadata": {}, "score": "73.10704"}
{"text": "Cardiac duplex ultrasound image ( 4-chamber view ) , obtained 2 days after thrombolysis showing the thrombus attached to left ventricular apex ( arrow ) .", "label": "", "metadata": {}, "score": "73.270355"}
{"text": "Cerebral MRI , twenty - four hours after lysis revealed a cortical infarct with a clinically asymptomatic haemorrhagic transformation in the left - sided MCA territory .", "label": "", "metadata": {}, "score": "73.281006"}
{"text": "View Article PubMed .Kono , et al .: Left ventricular wall motion abnormalities in patients with subarachnoid hemorrhage : neurogenic stunned myocardium .J Am Coll Cardiol 1994 , 24 : 636 - 640 .", "label": "", "metadata": {}, "score": "73.51584"}
{"text": "Extracranial Duplexsonography revealed moderate arteriosclerotic plaque formation in the carotid bulb on both sides but no hemodynamic stenosis of the carotid and vertebral arteries .Using transcranial duplexsonography a severe stenosis was found in the proximal segment of the left middle cerebral artery .", "label": "", "metadata": {}, "score": "74.01807"}
{"text": "The long TIP is now 0.58 % -7/16 ! ! !- performing miserably since setting a new ( record ? ) low of 0.36 % on 4/5 , and now above the 0.55 % recent high !", "label": "", "metadata": {}, "score": "74.42421"}
{"text": "TNKase should be given to pregnant women only if the potential benefits justify the potential risk to the fetus .Nursing Mothers .It is not known if TNKase is excreted in human milk .", "label": "", "metadata": {}, "score": "74.80615"}
{"text": "Clinical Studies .ASSENT-2 was an international , randomized , double - blind trial that compared 30-day mortality rates in 16,949 patients assigned to receive an IV bolus dose of TNKase or an accelerated infusion of Activase \u00ae ( Alteplase ) .", "label": "", "metadata": {}, "score": "75.22435"}
{"text": "An analysis of the UK Clinical Practice Research Datalink database found ... read more .The researchers in this study set out to determine the relationship between objectively measured sleep ... read more .", "label": "", "metadata": {}, "score": "75.76184"}
{"text": "Drug / Laboratory Test Interactions .During TNKase therapy , results of coagulation tests and/or measures of fibrinolytic activity may be unreliable unless specific precautions are taken to prevent in vitro artifacts .", "label": "", "metadata": {}, "score": "75.83099"}
{"text": "Ohtsuka , et al .: Neurogenic stunned myocardium .Circulation 2000 , 101 : 2122 - 2124 .PubMed .Bernstein R , Mayer SA , Magnano A : Neurogenic stunned myocardium in Guillaine - Barre syndrome .", "label": "", "metadata": {}, "score": "75.98998"}
{"text": "It is well above Sup / Res at the 40 day ( $ 92.89 ) , 50 day ( $ 92.63 ) and 200 day ( $ 91.93 ) .", "label": "", "metadata": {}, "score": "76.16269"}
{"text": "Standard heparin and LMW heparin are not associated with an increase in major bleeding in ischemic coronary syndromes , but are associated with an increase in major bleeding in ischemic stroke .", "label": "", "metadata": {}, "score": "76.32759"}
{"text": "Conservative approach to revascularization is safe .ScienceDaily .Cardiovascular Research Foundation . \"Conservative approach to revascularization is safe . \"ScienceDaily .Left untreated , depression could have implications for a fetus 's health .", "label": "", "metadata": {}, "score": "76.40727"}
{"text": "Allergic Reactions .When such reactions occur , they usually respond to conventional therapy .Other Adverse Reactions .The following adverse reactions have been reported among patients receiving TNKase in clinical trials .", "label": "", "metadata": {}, "score": "76.82415"}
{"text": "In contrast , in the SPAF III trial ( targeted INR 2.0 to 3.0 ) , the mean age was 71 years and the rate of intracranial hemorrhage was 0.5%/yr .", "label": "", "metadata": {}, "score": "76.99034"}
{"text": "In clinical studies of TNKase , patients were treated with both aspirin and heparin .Heparin may contribute to the bleeding risks associated with TNKase .", "label": "", "metadata": {}, "score": "77.27284"}
{"text": "new 52 week highs have ranged from 121 - 709 , fell back to 499 vs 786 vs 411 vs 386 vs 486 vs 418 vs 267 vs 495 vs 400 vs 400 vs 237 vs 228 vs 106 vs 100 .", "label": "", "metadata": {}, "score": "77.42297"}
{"text": "Circulation 1998;98:2805 - 14 .Van de Werf F , Cannon CP , Luyten A , Houbracken K , McCabe CH , Berioli S , et al .", "label": "", "metadata": {}, "score": "77.591095"}
{"text": "Heparin effects can be reversed by protamine .Readministration .Readministration of plasminogen activators , including TNKase , to patients who have received prior plasminogen activator therapy has not been systematically studied .", "label": "", "metadata": {}, "score": "77.940674"}
{"text": "However , the presence of the antibiotic is not detectable in the final product ( limit of detection is 0.67 \u00b5g / vial ) .TNKase is a sterile , white to off - white , lyophilized powder for single intravenous ( IV ) bolus administration after reconstitution with Sterile Water for Injection ( SWFI ) , USP .", "label": "", "metadata": {}, "score": "78.214935"}
{"text": "In addition , our patient suffered from coronary artery disease whereas neurogenic myocardial stunning has been reported in patients without cardiac disease .Finally , the cardiac failure in our patient occurred on the 3 rd day and not directy after stroke which makes the diagnosis of neurogenic stunned myocardium further unlikely [ 17 , 20 , 21 ] .", "label": "", "metadata": {}, "score": "78.32402"}
{"text": "L. , V.P. , E.D.L. , R.V. , H.S. , and G.W.S. interpreted data .M.T.D. , C.S. , H.K. , M.S. , L.T. , B.v.d . H. , M.A.V. , C.K. , C.M. , T.C. , G.S. , L.S.D.d.l .", "label": "", "metadata": {}, "score": "78.32651"}
{"text": "TNKase does not elicit maternal and embryo toxicity in rabbits following a single IV administration .Thus , in developmental toxicity studies conducted in rabbits , the no observable effect level ( NOEL ) of a single IV administration of TNKase on maternal or developmental toxicity was 5 mg / kg ( approximately 8 - 10 times the human dose ) .", "label": "", "metadata": {}, "score": "78.705124"}
{"text": "The range since 2/11 is 558 M to 1.825B on 3/15 's options expiry and a near 12 month high , second only to 12/21 's 1.88B shares .", "label": "", "metadata": {}, "score": "78.92479"}
{"text": "Stroke Prevention in Atrial Fibrillation Investigators .Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : Stroke Prevention in Atrial Fibrillation II Study .", "label": "", "metadata": {}, "score": "79.77509"}
{"text": "Stroke Prevention in Atrial Fibrillation Investigators .Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : Stroke Prevention in Atrial Fibrillation II Study .", "label": "", "metadata": {}, "score": "79.77509"}
{"text": "Details of the method used to select relevant articles can be found in the five previous symposia of the American College of Chest Physicians ( ACCP ) .", "label": "", "metadata": {}, "score": "79.854706"}
{"text": "The average last week was a weak 720 M shares vs 687 M vs 859 M vs 689 M ! ! !The last options expiry came in at a solid but not great 914 M shares .", "label": "", "metadata": {}, "score": "79.873566"}
{"text": "P 5.29 .From 262 observations 2006 Oct. 2 - 2011 Dec. 17 , mean residual 0\".6 .T 2006 Oct. 7.43146 TT MPC .q 0.9895425 ( 2000.0 ) P Q .", "label": "", "metadata": {}, "score": "79.900894"}
{"text": "Each vial will deliver 50 mg of Tenecteplase .TNKase - Clinical Pharmacology .General .Tenecteplase is a modified form of human tissue plasminogen activator ( tPA ) that binds to fibrin and converts plasminogen to plasmin .", "label": "", "metadata": {}, "score": "80.20018"}
{"text": "Finally , the levels of LDL , triglyceride , and BMI were not collected in our database .Their availability certainly would have improved our results .", "label": "", "metadata": {}, "score": "80.89315"}
{"text": "BofA only ' most active ' financial rose 4.6 % ! ! ! to $ 12.80 + .56 ( on a settlement with MBIA that cost them money but gave them a piece of the company ? ?", "label": "", "metadata": {}, "score": "80.9118"}
{"text": "Drug Interactions .Formal interaction studies of TNKase with other drugs have not been performed .Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin .", "label": "", "metadata": {}, "score": "80.9314"}
{"text": "N / A N / A N / A 0.2 -0.7 -0.4 -0.4 -0.4 0.1 .See footnotes at end of table .[ [ Page 309 ] ] .", "label": "", "metadata": {}, "score": "81.173355"}
{"text": "Acknowledgments .M.S. received research grants from Boston Scientific , Medtronic , and Biotronik .C.K. is on the advisory board at Ely Lilly and received research / travel support from Abbott Vascular .", "label": "", "metadata": {}, "score": "81.34378"}
{"text": "Superficial or surface bleeding , observed mainly at vascular puncture and access sites ( e.g. , venous cutdowns , arterial punctures ) or sites of recent surgical intervention .", "label": "", "metadata": {}, "score": "81.396515"}
{"text": "-0.2 -1.2 -1.5 0.5 -0.3 -2.2 -1.9 -1.3 -0.3 .See footnotes at end of table .[ [ Page 310 ] ] .Table 14.2 - -FEDERAL TRANSACTIONS IN THE NATIONAL INCOME AND PRODUCT ACCOUNTS AS PERCENTAGES OF GDP FOR FEDERAL FISCAL YEARS : 1948 - 2008 - -Continued .", "label": "", "metadata": {}, "score": "81.7324"}
{"text": "-3.1 -3.5 -2.4 -1.8 -0.9 -2.1 -2.0 -3.6 -5.6 .See footnotes at end of table .[ [ Page 311 ] ] .Table 14.2 - -FEDERAL TRANSACTIONS IN THE NATIONAL INCOME AND PRODUCT ACCOUNTS AS PERCENTAGES OF GDP FOR FEDERAL FISCAL YEARS : 1948 - 2008 - -Continued .", "label": "", "metadata": {}, "score": "81.871605"}
{"text": "Note : Do not discard the shield assembly .Inject the entire contents of the syringe ( 10 mL ) into the TNKase vial directing the diluent stream into the powder .", "label": "", "metadata": {}, "score": "82.00683"}
{"text": "e 0.6723986 Incl .P 5.25 .From 262 observations 2006 Oct. 2 - 2011 Dec. 17 , mean residual 0\".63 .Residuals in seconds of arc .", "label": "", "metadata": {}, "score": "82.52132"}
{"text": "Pediatric Use .The safety and effectiveness of TNKase in pediatric patients have not been established .Geriatric Use .Of the patients in ASSENT-2 who received TNKase , 4,958 ( 59 % ) were under the age of 65 ; 2,256 ( 27 % ) were between the ages of 65 and 74 ; and 1,244 ( 15 % ) were 75 and over .", "label": "", "metadata": {}, "score": "82.9355"}
{"text": "Findings of the SMART - CASE trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics ( TCT ) scientific symposium .Sponsored by the Cardiovascular Research Foundation ( CRF ) , TCT is the world 's premier educational meeting specializing in interventional cardiovascular medicine .", "label": "", "metadata": {}, "score": "82.996185"}
{"text": "Current Transfer payments ............................ 4.0 4.6 5.1 5.2 5.6 5.6 5.6 5.4 5.3 .Government social benefits .........................( 3.0 ) ( 3.6 ) ( 3.7 ) ( 3.7 ) ( 4.2 ) ( 4.1 ) ( 4.1 ) ( 3.9 ) ( 3.8 ) .", "label": "", "metadata": {}, "score": "83.44604"}
{"text": "Current Transfer payments ............................ 4.9 5.3 6.3 3.9 3.6 3.5 3.6 4.0 3.8 .Government social benefits .........................( 3.2 ) ( 2.8 ) ( 3.9 ) ( 2.3 ) ( 2.3 ) ( 2.3 ) ( 2.6 ) ( 2.9 ) ( 2.8 ) .", "label": "", "metadata": {}, "score": "83.599686"}
{"text": "Current Transfer payments ....................................... 11.0 11.7 12.1 12.0 11.9 11.8 12.0 11.9 .Government social benefits .................................... ( 8.2 ) ( 8.7 ) ( 8.8 ) ( 8.7 ) ( 8.7 ) ( 8.8 ) ( 9.0 ) ( 9.0 ) .", "label": "", "metadata": {}, "score": "83.69"}
{"text": "Heparin has the potential to induce bleeding by inhibiting blood coagulation , by impairing platelet function , 120 and by increasing capillary permeability .121 Heparin can also produce thrombocytopenia , but this is rarely an important cause of bleeding .", "label": "", "metadata": {}, "score": "83.691284"}
{"text": "Current Transfer payments ....................................... 11.4 11.4 11.4 11.3 11.1 10.9 10.7 10.5 .Government social benefits .................................... ( 8.7 ) ( 8.7 ) ( 8.7 ) ( 8.7 ) ( 8.6 ) ( 8.3 ) ( 8.0 ) ( 7.9 ) .", "label": "", "metadata": {}, "score": "83.983475"}
{"text": "( 2.7 ) ( 2.9 ) ( 3.0 ) ( 3.0 ) ( 2.9 ) ( 2.8 ) ( 2.7 ) ( 2.6 ) .Other transfers to the rest of the world ......................", "label": "", "metadata": {}, "score": "84.22615"}
{"text": "12 Branch , Terra ...... 27 - 0 406 15.0 61 - 165 .370 19 - 59 .322 20 - 27 .741 14 17 31 1.1 28 0 18 47 1 20 161 6.0 .", "label": "", "metadata": {}, "score": "84.24783"}
{"text": "vs +1.6x ( also compare +3.4x , 3.9x , -10.5x ! ! !, +6.4x , -7.2x ) on NYSE and +1.5x vs +2.5x vs +2.9x vs -2.7x ( compare +3x , -3x ! , -5.2x , +6.2x , -12.8x .", "label": "", "metadata": {}, "score": "84.41559"}
{"text": "-0.5 % , Dow 30 +1 % vs +0.9 % vs -0.9 % .REAL NYSE Volume also plunged to a weak 619 M shares from a weak 716 M vs 643 M vs 697 M vs 887 M vs 599 M shares ( lowest since 4/8) .... indicative of a total absence of retail !", "label": "", "metadata": {}, "score": "84.49631"}
{"text": "Conservative revascularization using criteria of 70 percent diameter stenosis was found to be non - inferior to aggressive revascularization , \" said the lead investigator Hyeon - Cheol Gwon , MD , PhD. Dr. Gwon is a Professor at the Samsung Medical Center in Seoul , South Korea .", "label": "", "metadata": {}, "score": "84.666504"}
{"text": "From the information below , follow the instructions applicable to the IV system in use .Remove the shield and use the blunt plastic cannula to access the split septum injection port .", "label": "", "metadata": {}, "score": "85.08054"}
{"text": "[ [ Page 308 ] ] .Table 14.2 - -FEDERAL TRANSACTIONS IN THE NATIONAL INCOME AND PRODUCT ACCOUNTS AS PERCENTAGES OF GDP FOR FEDERAL FISCAL YEARS : 1948 - 2008 - -Continued .", "label": "", "metadata": {}, "score": "85.2148"}
{"text": ": 10 yr Treasury 1.78 % -3/16 vs 1.74 % ( recent range 2.06 % to 1.63 % ! ! ! ) , and the 30 yr 's 3.26 % to 2.82 % ! ! !", "label": "", "metadata": {}, "score": "85.22102"}
{"text": "( 2.4 ) ( 2.5 ) ( 2.5 ) ( 2.5 ) ( 2.4 ) ( 2.4 ) ( 2.5 ) ( 2.5 ) .Other transfers to the rest of the world ......................", "label": "", "metadata": {}, "score": "85.2314"}
{"text": "[ [ Page 313 ] ] .Table 14.2 - -FEDERAL TRANSACTIONS IN THE NATIONAL INCOME AND PRODUCT ACCOUNTS AS PERCENTAGES OF GDP FOR FEDERAL FISCAL YEARS : 1948 - 2008 - -Continued .", "label": "", "metadata": {}, "score": "85.38335"}
{"text": "[ [ Page 81 ] ] .Table 4.2 - -PERCENTAGE DISTRIBUTION OF OUTLAYS BY AGENCY : 1962 - 2012 - -Continued .Department or other unit 1979 1980 1981 1982 1983 1984 1985 1986 1987 .", "label": "", "metadata": {}, "score": "85.43804"}
{"text": "Pressure should be applied for at least 30 minutes , a pressure dressing applied , and the puncture site checked frequently for evidence of bleeding .", "label": "", "metadata": {}, "score": "85.47356"}
{"text": "ALL GAMES ...........( 8 - 19 ) ( 4 - 9 ) ( 3 - 10 ) ( 1 - 0 ) .CONFERENCE .......... ( 3 - 17 ) ( 2 - 8 ) ( 1 - 9 ) ( 0 - 0 ) .", "label": "", "metadata": {}, "score": "85.590866"}
{"text": "98 - 337 .291 300 - 465 .6451454 72.7 .TOTALS O - REB D - REB TOTAL PF FO A TO A / TO Hi Pts O - REB D - REB TOTAL PF FO A TO A / TO Hi Pts .", "label": "", "metadata": {}, "score": "85.950226"}
{"text": "( 8 - 19 ) ( 4 - 9 ) ( 3 - 10 ) ( 1 - 0 ) .CONFERENCE .......... ( 3 - 17 ) ( 2 - 8 ) ( 1 - 9 ) ( 0 - 0 ) .", "label": "", "metadata": {}, "score": "86.00419"}
{"text": "Am Heart J 1999;137:786 - 91 .About .Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .", "label": "", "metadata": {}, "score": "86.01851"}
{"text": "Another hypothesis for the temporary cardiac detoriation in our patient could be an acute neurogenic stunned myocardium .This phenomenon is described as sudden , reversible left ventricular dysfunction with abnormal left ventricular wall motion and reduced ejection fraction .", "label": "", "metadata": {}, "score": "86.13601"}
{"text": "Volatility ( S&P VIX ) declined again to 12.66 -.19 , with a very tight range of 12.75 - 13.19 , compare to Thurs / Friday 's 13.58 - 14.48 .", "label": "", "metadata": {}, "score": "86.18287"}
{"text": "RESEARCH DESIGN AND METHODS .Our population is represented by STEMI patients included in the DESERT cooperation .Detailed data have been previously described ( 19 ) .", "label": "", "metadata": {}, "score": "86.47859"}
{"text": "Biological potency is determined by an in vitro clot lysis assay and is expressed in Tenecteplase - specific units .The specific activity of Tenecteplase has been defined as 200 units / mg .", "label": "", "metadata": {}, "score": "86.48186"}
{"text": "( On - budget ) ........................................ ( -4.8 ) ( -4.8 ) ( -5.6 ) ( -5.2 ) ( -5.9 ) ( -5.5 ) ( -5.5 ) ( -5.8 ) ( -6.3 ) .", "label": "", "metadata": {}, "score": "86.53819"}
{"text": "( 5 - 2 ) ( 2 - 1 ) ( 2 - 1 ) ( 1 - 0 ) .DATE TIME OPPONENT SCORE ATTEND HIGH POINTS HIGH REBOUNDS .", "label": "", "metadata": {}, "score": "86.56488"}
{"text": "Statistical analysis was performed with the SPSS 15.0 statistical package .Continuous data were expressed as mean \u00b1 SD and categorical data as percentage .The ANOVA was appropriately used for continuous variables .", "label": "", "metadata": {}, "score": "86.654526"}
{"text": "Observer R. A. Kowalski .Measurers J. D. Ahern , . E. C. Beshore , A. Boattini , A. R. Gibbs , A. D. Grauer , R. E. Hill , .", "label": "", "metadata": {}, "score": "86.85371"}
{"text": "Other Independent Agencies ( On - budget ) ............... 2.1 1.5 1.0 1.5 1.9 2.3 2.4 1.6 2.2 .Undistributed offsetting receipts .................... -6.3 -6.5 -6.2 -6.5 -6.3 -6.1 -6.0 -6.0 -6.4 .", "label": "", "metadata": {}, "score": "86.94324"}
{"text": "Advancers ran 52/47 vs 84/16 .So let 's see what else happened : . ; Russell 2000 +0.6 % vs +1.6 % vs +1.7 % vs -2.3 % ; Dow Utilities DOWN 1.4 % vs -0.3 % vs -0.2 % vs -1 % !", "label": "", "metadata": {}, "score": "87.254715"}
{"text": "( On - budget ) ........................................( -6.3 ) ( -6.4 ) ( -6.2 ) ( -6.3 ) ( -6.3 ) ( -6.1 ) ( -6.0 ) ( -6.5 ) ( -5.9 ) .", "label": "", "metadata": {}, "score": "87.31668"}
{"text": "Data sources include Micromedex \u00ae ( updated Jan 25th , 2016 ) , Cerner Multum \u2122 ( updated Feb 1st , 2016 ) , Wolters Kluwer \u2122 ( updated Feb 1st , 2016 ) and others .", "label": "", "metadata": {}, "score": "87.34526"}
{"text": "Note : The shield assembly also contains the clear - ended blunt plastic cannula ; retain for split septum IV access .Administration .The product should be visually inspected prior to administration for particulate matter and discoloration .", "label": "", "metadata": {}, "score": "87.41594"}
{"text": "11/22/08 FLORIDA SOUTHERN L 67 - 79 172 .11/25/08 TOCCOA FALLS W 95 - 48 102 .11/28/08 at Eckerd W 75 - 74 75 .", "label": "", "metadata": {}, "score": "87.46619"}
{"text": "G.D.L. had full access to the data and takes full responsibility for this work as a whole , including the study design and the decision to submit and publish the manuscript .", "label": "", "metadata": {}, "score": "87.94074"}
{"text": "How far ?Dunno , but yesterday 's feeble markets following a major rally on no significant volume suggests it .The best , and only double digit performer yesterday ( the best sectors were up 0.6 % ) , was Dow Transports +1.3 % following their also best 2.1 % gain on Friday .", "label": "", "metadata": {}, "score": "88.02811"}
{"text": "Today ? -5 on an inside day with a range of just 47 points ? ? ?One day wonder is putting it mildly when you ca n't even muster support for follow - thru !", "label": "", "metadata": {}, "score": "88.04229"}
{"text": "Hadley , Arile .......34 - 87 .391 2 - 11 .182 19 - 27 .704 89 3.3 22 - 64 .344 1 - 8 .125 16 - 22 .727 61 3.1 .", "label": "", "metadata": {}, "score": "88.28528"}
{"text": "-3.3 -2.2 -1.5 -0.5 -1.6 -1.7 -3.1 -5.2 .Addendum : Total Receipts and Expenditures .Current receipts ..................................... 17.6 17.5 18.0 18.3 18.9 19.0 19.7 19.3 18.2 .", "label": "", "metadata": {}, "score": "88.3121"}
{"text": "Resistance remains way above at the 40 day/50 day : $ 1523 - 1535 - still falling !Overnight it is $ 1449.00 -$19 ! ! !", "label": "", "metadata": {}, "score": "88.31409"}
{"text": "4/18 's low of $ 85.61 was lowest since 12/11 !The range is now $ 85.61-$97.80 since June 29 , 2012 ! ! ! !", "label": "", "metadata": {}, "score": "88.43086"}
{"text": "See footnotes at end of table .[ [ Page 312 ] ] .Table 14.2 - -FEDERAL TRANSACTIONS IN THE NATIONAL INCOME AND PRODUCT ACCOUNTS AS PERCENTAGES OF GDP FOR FEDERAL FISCAL YEARS : 1948 - 2008 - -Continued .", "label": "", "metadata": {}, "score": "88.54199"}
{"text": "( On - budget ) ...................................................( -6.7 ) ( -6.5 ) ( -5.9 ) ( -5.9 ) ( -6.1 ) ( -5.7 ) ( -5.4 ) ( -5.0 ) .", "label": "", "metadata": {}, "score": "88.76253"}
{"text": "Table 4.2 - -PERCENTAGE DISTRIBUTION OF OUTLAYS BY AGENCY : 1962 - 2012 .Department or other unit 1962 1963 1964 1965 1966 1967 1968 1969 1970 .", "label": "", "metadata": {}, "score": "88.99269"}
{"text": "( 1.9 ) ( 1.9 ) ( 2.0 ) ( 1.8 ) ( 1.8 ) ( 1.8 ) ( 1.9 ) ( 2.1 ) ( 2.3 ) .", "label": "", "metadata": {}, "score": "89.23117"}
{"text": "[ [ Page 82 ] ] .Table 4.2 - -PERCENTAGE DISTRIBUTION OF OUTLAYS BY AGENCY : 1962 - 2012 - -Continued .Department or other unit 1988 1989 1990 1991 1992 1993 1994 1995 1996 .", "label": "", "metadata": {}, "score": "89.25214"}
{"text": "17.1 17.6 18.0 19.6 18.7 17.3 17.5 17.8 18.3 .Current Expenditures .Consumption expenditures ............................. 9.4 10.2 10.6 10.2 9.8 9.3 9.0 8.3 7.8 .", "label": "", "metadata": {}, "score": "89.2763"}
{"text": "NON - CONFERENCE ......( 5 - 2 ) ( 2 - 1 ) ( 2 - 1 ) ( 1 - 0 ) .# # Player GP - GS Min -- Avg FG - FGA Pct 3FG - FGA Pct FT - FTA Pct Off Def Tot Avg PF FO A TO Blk Stl Pts Avg . 3 Billings , Tiandra .", "label": "", "metadata": {}, "score": "89.40172"}
{"text": "( 5 - 2 ) ( 2 - 1 ) ( 2 - 1 ) ( 1 - 0 ) . . .DATE OPPONENT W / L SCORE ATTEND .", "label": "", "metadata": {}, "score": "89.41901"}
{"text": "No other potential conflicts of interest relevant to this article were reported .G.D.L. and G.W.S. conceived and designed the study .G.D.L. performed statistical analysis and drafted the manuscript .", "label": "", "metadata": {}, "score": "89.64789"}
{"text": "How is TNKase Supplied .TNKase \u00ae ( Tenecteplase ) is supplied as a sterile , lyophilized powder in a 50 mg vial under partial vacuum .", "label": "", "metadata": {}, "score": "89.99424"}
{"text": "Branch , Terra ....... 61 - 165 .370 19 - 59 .322 20 - 27 .741 161 6.0 42 - 132 .31815 - 49 .306 12 - 18 .667 111 5.6 .", "label": "", "metadata": {}, "score": "90.04578"}
{"text": "Corbett , Clarissa ... 26 1 .Georgia Southwestern Overall / Conference Statistics ( as of Feb 28 , 2009 ) .All games .SUMMARY GP - GS Min / G FG% 3PT% FT% R / G A / G STL BLK PTS / G GP - GS Min / G FG% 3PT% FT% R / G A / G STL BLK PTS / G .", "label": "", "metadata": {}, "score": "90.152115"}
{"text": "[ [ Page 307 ] ] .Table 14.2 - -FEDERAL TRANSACTIONS IN THE NATIONAL INCOME AND PRODUCT ACCOUNTS AS PERCENTAGES OF GDP FOR FEDERAL FISCAL YEARS : 1948 - 2008 .", "label": "", "metadata": {}, "score": "90.23051"}
{"text": "Opponents ........... 27 673 - 1590 .423 131 - 447 .293 398 - 610 .652 1875 69.4 .REBOUNDS .TOTALS GP MIN OFF DEF TOT PF FO A TO A / TO HI .", "label": "", "metadata": {}, "score": "90.244865"}
{"text": "[ [ Page 83 ] ] .Table 4.2 - -PERCENTAGE DISTRIBUTION OF OUTLAYS BY AGENCY : 1962 - 2012 - -Continued .Department or other unit 1997 1998 1999 2000 2001 2002 2003 2004 .", "label": "", "metadata": {}, "score": "90.39642"}
{"text": "Once the appropriate dose of TNKase is drawn into the syringe , stand the shield vertically on a flat surface ( with green side down ) and passively recap the red hub cannula .", "label": "", "metadata": {}, "score": "90.46461"}
{"text": "( -5.5 ) ( -5.8 ) ( -5.4 ) ( -5.7 ) ( -5.5 ) ( -5.3 ) ( -5.2 ) ( -5.1 ) ( -5.3 ) .", "label": "", "metadata": {}, "score": "90.53509"}
{"text": "( 1.1 ) ( 1.3 ) ( 1.5 ) ( 1.4 ) ( 1.7 ) ( 2.0 ) ( 2.3 ) ( 2.6 ) ( 2.4 ) .", "label": "", "metadata": {}, "score": "90.609886"}
{"text": "Undistributed offsetting receipts .................... -7.1 -6.4 -7.7 -8.7 -6.4 -6.0 -4.7 -5.6 -5.3 .( On - budget ) ........................................( -5.8 ) ( -5.2 ) ( -6.5 ) ( -7.4 ) ( -5.3 ) ( -5.0 ) ( -4.3 ) ( -4.7 ) ( -4.5 ) .", "label": "", "metadata": {}, "score": "90.66524"}
{"text": "D88 1.3- 0.8 + 061020 J63 0.1 + 0.1 + 061201 349 ( 2.0 + 1.5 + ) .061008D88 0.8- 0.8 + 061020 G92 ( 4.2- 1.6 + ) 111217 G96 1.3- 0.1 + .", "label": "", "metadata": {}, "score": "90.69414"}
{"text": "Total outlays ............................................. 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 .[ [ Page 84 ] ] .Table 4.2 - -PERCENTAGE DISTRIBUTION OF OUTLAYS BY AGENCY : 1962 - 2012 - -Continued .", "label": "", "metadata": {}, "score": "90.705"}
{"text": "98 3.8 .Branch , Terra ....... 27 61 - 165 .370 19 - 59 .322 20 - 27 .741 161 6.0 .Elkins , Sylvia ......", "label": "", "metadata": {}, "score": "90.730316"}
{"text": "Orbital elements : .T 2012 Jan. 14.93632 TT MPC . q 1.0074539 ( 2000.0 ) P Q .n 0.18623619 Peri . a 3.0368732 Node 279.74496 +0.90437293 -0.01692736 .", "label": "", "metadata": {}, "score": "90.80214"}
{"text": "Nondefense .........................................( 2.4 ) ( 2.3 ) ( 2.3 ) ( 2.2 ) ( 2.2 ) ( 2.3 ) ( 2.3 ) ( 2.2 ) ( 2.3 ) .", "label": "", "metadata": {}, "score": "90.86592"}
{"text": "( 0.1 ) ( 0.1 ) ( 0.1 ) ( 0.1 ) ( 0.1 ) ( 0.1 ) ( 0.1 ) ( 0.1 ) .Contributions for gov . social insurance ......................... 7.1 7.0 6.9 6.8 6.9 6.8 6.9 6.9 .", "label": "", "metadata": {}, "score": "91.02428"}
{"text": "22.4 22.4 22.3 22.1 22.6 22.0 21.4 21.0 .Other Independent Agencies ( On - budget ) ..........................-0.2 0.7 0.4 0.5 0.6 0.8 0.7 0.4 .", "label": "", "metadata": {}, "score": "91.17134"}
{"text": "[ [ Page 80 ] ] .Table 4.2 - -PERCENTAGE DISTRIBUTION OF OUTLAYS BY AGENCY : 1962 - 2012 - -Continued .Department or other unit 1971 1972 1973 1974 1975 1976 TQ 1977 1978 .", "label": "", "metadata": {}, "score": "91.21639"}
{"text": "Gently swirl until contents are completely dissolved .DO NOT SHAKE .The reconstituted preparation results in a colorless to pale yellow transparent solution containing TNKase at 5 mg / mL at a pH of approximately 7.3 .", "label": "", "metadata": {}, "score": "91.234375"}
{"text": "Income receipts on assets ............................ 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 .Current transfer receipts ............................ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 .", "label": "", "metadata": {}, "score": "91.47404"}
{"text": "Net purchases of nonproduced assets .................. N / A N / A N / A 0.1 0.1 0.1 0.1 0.1 0.1 .Total expenditures ................................. N / A N / A N / A 17.9 18.5 18.7 18.7 18.4 17.3 .", "label": "", "metadata": {}, "score": "91.4881"}
{"text": "361 ( 0.7- 1.6- ) 061019 G92 ( 3.8- 2.6 + ) 061124 G92 ( 6.9 + 1.1- ) .061007361 1.3- 0.4 + 061020 A79 0.5 + 1.1 + 061124 G92 ( 2.5 + 0.1- ) .", "label": "", "metadata": {}, "score": "91.49218"}
{"text": "There have been just fifteen 800+M shares in 2013 - just 4 up , 11 down , but on trades of less than that 72 have been up and just 19 down ... there have been 19 mixed sessions ... hint : low volume rallies ! ! !", "label": "", "metadata": {}, "score": "91.540146"}
{"text": "061003 361 0.9- 0.3 + 061015 461 1.3 + 0.6- 061031 H07 0.2- 0.5 + . 061004J95 0.2- 0.0 061015 461 1.4 + 0.4- 061031 H07 1.4 + 0.3- .", "label": "", "metadata": {}, "score": "91.61077"}
{"text": "Income receipts on assets ............................ 0.3 0.3 0.3 0.4 0.4 0.5 0.6 0.7 0.7 .Current transfer receipts ............................ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 .", "label": "", "metadata": {}, "score": "91.71397"}
{"text": "12 Branch , Terra ....... 27 - 0 15.0 .370 .322 .741 1.1 0.7 20 1 6.0 .14 Elkins , Sylvia ...... 17 - 1 5.5 .222 .200 .500 0.5 0.4 3 0 1.1 .", "label": "", "metadata": {}, "score": "91.77303"}
{"text": "( N / A ) ( N / A ) ( N / A ) ( 0.3 ) ( 0.4 ) ( 0.5 ) ( 0.5 ) ( 0.6 ) ( 0.6 ) .", "label": "", "metadata": {}, "score": "91.88608"}
{"text": "23 James , Monica ....... 12 - 1 5.1 .217 .000 .333 0.3 0.3 2 0 1.0 .25 Thomas , Krystal ..... 22 - 0 9.5 .313 .211 .571", "label": "", "metadata": {}, "score": "91.89758"}
{"text": "Social Security Administration ( Off - budget ) .......... 20.1 19.9 19.6 20.1 20.4 21.2 21.5 21.8 22.0 .Other Independent Agencies ( On - budget ) ............... 1.8 2.7 5.5 5.8 1.0 -1.2 0.2 -0.4 0.2 .", "label": "", "metadata": {}, "score": "91.92766"}
{"text": "Even if it was High Freak induced ... it was FAUX ! ! !Volume slumped from an average 3.6B shares to just 3.05B !Real trades on the NYSE collapsed to 619 M from an average 716 M shares .", "label": "", "metadata": {}, "score": "91.94063"}
{"text": "( On - budget ) ...................................................( -5.0 ) ( -4.8 ) ( -5.2 ) ( -5.2 ) ( -5.2 ) ( -5.0 ) ( -5.1 ) ( -5.1 ) .", "label": "", "metadata": {}, "score": "92.1311"}
{"text": "( 1.9 ) ( 2.0 ) ( 2.0 ) ( 2.0 ) ( 1.8 ) ( 1.8 ) ( 1.9 ) ( 2.0 ) ( 2.1 ) .", "label": "", "metadata": {}, "score": "92.22087"}
{"text": "H06 0.0 0.3- 061015 372 0.5 + 0.7- 061109 850 ( 3.1 + 0.1 + ) . 061004H06 0.1- 0.1- 061015 361 0.2 + 0.3 + 061110", "label": "", "metadata": {}, "score": "92.25142"}
{"text": "( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) .", "label": "", "metadata": {}, "score": "92.30875"}
{"text": "( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) .", "label": "", "metadata": {}, "score": "92.30875"}
{"text": "( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) .", "label": "", "metadata": {}, "score": "92.30875"}
{"text": "The Fed ! ! !and when it is perceived that the pace is slowing look out below .Yesterday , the Nasdaq 100 was up a paltry 0.4 % or 10.8 points .", "label": "", "metadata": {}, "score": "92.31792"}
{"text": "Social Security Administration ( Off - budget ) .......... 20.5 19.9 20.5 20.8 18.6 20.1 19.4 19.3 20.2 .Other Independent Agencies ( On - budget ) ............... 2.0 2.4 1.7 1.2 1.1 1.0 0.7 0.9 1.0 .", "label": "", "metadata": {}, "score": "92.32316"}
{"text": "Net purchases of nonproduced assets .................. N / A N / A N / A N / A N / A N / A N / A N / A N / A .", "label": "", "metadata": {}, "score": "92.554855"}
{"text": "The ICH rates were 0.4 % in patients under the age of 65 , 1.6 % in patients between the ages of 65 and 74 , and 1.7 % in patients age 75 and over .", "label": "", "metadata": {}, "score": "92.55875"}
{"text": "Nondefense .......................................( 0.6 ) ( 0.6 ) ( 0.5 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) .", "label": "", "metadata": {}, "score": "92.59418"}
{"text": "Thomas , Krystal ..... 26 - 83 .313 4 - 19 .211 8 - 14 .571 64 2.9 10 - 46 .217 1 - 10 .100 6 - 9 .667 27 1.7 .", "label": "", "metadata": {}, "score": "92.6147"}
{"text": "Office of Personnel Management .................................. 2.8 2.8 2.8 2.7 2.7 2.6 2.5 2.5 .Social Security Administration ( On - budget ) ...................... 2.1 2.3 2.4 2.5 2.1 2.3 2.1 2.1 .", "label": "", "metadata": {}, "score": "92.61899"}
{"text": "372 0.1- 0.1- 061016 693 ( 1.7 + 0.4- ) 061118 J95 ( 3.0 + 0.8- ) .061006 372 0.3- 0.9 + 061016 693 1.5 + 0.8 + 061119 G92 ( 2.0 + 0.3- ) .", "label": "", "metadata": {}, "score": "92.62012"}
{"text": "( N / A ) ( N / A ) ( N / A ) ( -0.2 ) ( -0.2 ) ( -0.2 ) ( -0.2 ) ( -0.2 ) ( -0.2 ) .", "label": "", "metadata": {}, "score": "92.62794"}
{"text": "International Assistance Programs ............................... 0.6 0.5 0.6 0.7 0.6 0.7 0.6 0.6 .National Aeronautics and Space Administration ................... 0.9 0.9 0.8 0.8 0.8 0.7 0.7 0.7 .", "label": "", "metadata": {}, "score": "92.877075"}
{"text": "( -0.7 ) ( -0.6 ) ( -0.5 ) ( -0.5 ) ( -0.4 ) ( -0.6 ) ( -0.7 ) ( -0.7 ) ( -0.9 ) .", "label": "", "metadata": {}, "score": "92.9916"}
{"text": "All Content CHEST Journal All Books ACCP / AAP Pediatric Pulmonary Board Review ACCP Sleep Medicine Board Review ACCP Critical Care Medicine Board Review ACCP Pulmonary Medicine Board Review Search .", "label": "", "metadata": {}, "score": "93.09396"}
{"text": "( -0.8 ) ( -0.7 ) ( -0.7 ) ( -0.8 ) ( -0.7 ) ( -0.8 ) ( -0.8 ) ( -0.9 ) ( -1.1 ) .", "label": "", "metadata": {}, "score": "93.130264"}
{"text": "( -1.2 ) ( -1.2 ) ( -1.2 ) ( -1.2 ) ( -1.1 ) ( -1.0 ) ( -0.4 ) ( -0.9 ) ( -0.8 ) .", "label": "", "metadata": {}, "score": "93.15343"}
{"text": "( -1.1 ) ( -1.4 ) ( -1.7 ) ( -2.0 ) ( -2.2 ) ( -2.4 ) ( -2.4 ) ( -2.6 ) ( -2.7 ) .", "label": "", "metadata": {}, "score": "93.16458"}
{"text": "TNKase Description .TNKase \u00ae ( Tenecteplase ) is a tissue plasminogen activator ( tPA ) produced by recombinant DNA technology using an established mammalian cell line ( Chinese Hamster Ovary cells ) .", "label": "", "metadata": {}, "score": "93.352264"}
{"text": "Income receipts on assets ............................ 0.7 0.7 0.7 0.6 0.6 0.5 0.5 0.6 0.4 .Current transfer receipts ............................ 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 .", "label": "", "metadata": {}, "score": "93.368805"}
{"text": "( 0.6 ) ( 0.7 ) ( 0.7 ) ( 0.8 ) ( 0.8 ) ( 0.8 ) ( 0.9 ) ( 1.0 ) ( 1.0 ) .", "label": "", "metadata": {}, "score": "93.40787"}
{"text": "372 0.0 0.2- 061017 048 0.3 + 0.4- 061119 G92 ( 4.5 + 0.7- ) .061007J95 0.3- 0.2 + 061017 048 0.6 + 0.5- 061121 850 ( 2.1 + 0.9 + ) .", "label": "", "metadata": {}, "score": "93.68996"}
{"text": "J77 0.3 + 0.0 061015 461 1.1 + 0.0 061103 J95 ( 2.6- 1.5 + ) .061004J77 0.6- 0.0 061015 349 0.8 + 0.2- 061103 J95 ( 3.9- 1.7 + ) .", "label": "", "metadata": {}, "score": "93.69524"}
{"text": "Government social benefits .........................( 3.8 ) ( 4.2 ) ( 4.5 ) ( 4.7 ) ( 5.0 ) ( 5.7 ) ( 5.9 ) ( 6.1 ) ( 6.4 ) .", "label": "", "metadata": {}, "score": "93.847176"}
{"text": "585 ( 6.0- 2.6 + ) 061020 A79 0.4- 0.9 + 061124 349 ( 2.6 + 1.2 + ) .061008585 ( 0.6- 1.7 + ) 061020 A79 0.3 + 0.0 061125 G92 ( 0.2 + 3.6 + ) .", "label": "", "metadata": {}, "score": "93.862366"}
{"text": "Current expenditures ................................. 22.1 22.5 22.5 22.1 21.5 21.3 21.5 21.7 22.7 .Net investment : .Gross government investment ........................ 1.6 1.7 1.8 1.8 1.6 1.5 1.5 1.5 1.4 .", "label": "", "metadata": {}, "score": "93.87538"}
{"text": "Nondefense .......................................( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) .", "label": "", "metadata": {}, "score": "93.986496"}
{"text": "Net investment : .Gross government investment ........................ N / A N / A N / A N / A N / A N / A N / A N / A N / A .", "label": "", "metadata": {}, "score": "94.06362"}
{"text": "585 0.6- 0.8 + 061020 J63 ( 1.0- 1.7 + ) 061125 G92 ( 7.6 + 3.0- ) .061008585 0.5 + 0.3- 061020 J63 ( 0.8- 2.9- ) 061125 G92 ( 2.4 + 1.3 + ) .", "label": "", "metadata": {}, "score": "94.06616"}
{"text": "( 1.0 ) ( 1.8 ) ( 1.6 ) ( 1.0 ) ( 0.8 ) ( 0.6 ) ( 0.5 ) ( 0.5 ) ( 0.4 ) .", "label": "", "metadata": {}, "score": "94.27162"}
{"text": "Avg / G BLOCKED SHOTS G No .Blk / G .Sharp , Jamilah ...... 27 89 3.3 Burris , Brandi ...... 26 15 0.6 .", "label": "", "metadata": {}, "score": "94.38487"}
{"text": "J77 0.2 + 0.4- 061015 461 1.4 + 0.7- 061031 372 ( 2.0- 0.8 + ) .061004J77 0.0 0.8- 061015 118 1.1 + 0.5- 061103 J95 ( 3.3- 1.4 + ) .", "label": "", "metadata": {}, "score": "94.45773"}
{"text": "Current tax receipts ............................................ 10.6 11.0 11.4 11.9 12.3 12.8 12.8 13.4 .Personal current taxes ........................................ ( 7.6 ) ( 7.7 ) ( 7.9 ) ( 8.4 ) ( 8.9 ) ( 9.4 ) ( 9.5 ) ( 10.2 ) .", "label": "", "metadata": {}, "score": "94.48224"}
{"text": "585 0.9 + 1.2 + 061021 G92 ( 2.5- 3.2 + ) .061003 461 0.2 + 0.5 + 061009349 0.3- 0.2 + 061021 G96 0.6 + 0.5- .", "label": "", "metadata": {}, "score": "94.53691"}
{"text": "Income receipts on assets ....................................... 0.4 0.3 0.3 0.3 0.3 0.3 0.2 0.3 .Current transfer receipts ....................................... 0.3 0.3 0.3 0.2 0.3 0.2 0.2 0.3 .", "label": "", "metadata": {}, "score": "94.58397"}
{"text": "361 0.1- 0.4 + 061020 A79 0.3 + 0.6 + 061124 G92 1.0 + 0.3 + . 061008585 ( 2.1- 0.5 + ) 061020 A79 1.2 + 0.6 + 061124 G92 ( 3.2 + 1.3- ) .", "label": "", "metadata": {}, "score": "94.62354"}
{"text": "061004 H07 ( 1.9- 1.1 + ) 061015 361 1.4 + 1.4- 061108 349 ( 3.4- 1.4 + ) .061004H07 1.2- 0.8 + 061015 372 0.4 + 0.6- 061109 850 0.5- 0.5 + . 061004", "label": "", "metadata": {}, "score": "94.9189"}
{"text": "Defense .......................................... ( -1.5 ) ( -1.5 ) ( -1.4 ) ( -1.4 ) ( -1.3 ) ( -1.3 ) ( -1.2 ) ( -1.1 ) ( -1.0 ) .", "label": "", "metadata": {}, "score": "94.98015"}
{"text": "Current Expenditures .Consumption expenditures ............................. 7.7 8.0 8.0 7.9 7.6 7.3 7.2 7.4 7.1 .Defense ............................................ ( 5.7 ) ( 6.0 ) ( 6.0 ) ( 6.0 ) ( 5.8 ) ( 5.5 ) ( 5.3 ) ( 5.4 ) ( 5.0 ) .", "label": "", "metadata": {}, "score": "95.01669"}
{"text": "( 0.5 ) ( 0.5 ) ( 0.4 ) ( 0.5 ) ( 0.4 ) ( 0.5 ) ( 0.5 ) ( 0.5 ) ( 0.4 ) .", "label": "", "metadata": {}, "score": "95.13365"}
{"text": "\" Cardiovascular Research Foundation . \"Conservative approach to revascularization is safe . \"ScienceDaily .ScienceDaily , 30 October 2013 . . .Cardiovascular Research Foundation .", "label": "", "metadata": {}, "score": "95.17522"}
{"text": "Government social benefits .........................( 8.0 ) ( 7.8 ) ( 7.7 ) ( 7.7 ) ( 7.5 ) ( 7.5 ) ( 7.6 ) ( 8.1 ) ( 8.7 ) .", "label": "", "metadata": {}, "score": "95.287964"}
{"text": "061003 G92 0.5 + 0.5- 061012 349 0.7- 0.9 + 061024 850 0.2- 0.4 + .061003 H06 0.8 + 0.3- 061013 J63 ( 2.4- 1.4 + ) 061025 442 ( 4.5- 4.1 + ) .", "label": "", "metadata": {}, "score": "95.33748"}
{"text": "D88 0.7- 0.5 + 061020 G92 ( 3.2- 2.3 + ) 111217 G96 0.2 + 0.5 + .061008349 0.6- 0.5 + 061020 G92 ( 3.5- 0.8 + ) 111217 G96 0.3- 0.1 + .", "label": "", "metadata": {}, "score": "95.35749"}
{"text": "Current tax receipts ................................. 11.9 11.9 12.2 12.3 12.8 12.7 13.1 12.3 11.2 .Personal current taxes .............................( 7.9 ) ( 7.6 ) ( 8.0 ) ( 8.1 ) ( 8.7 ) ( 8.9 ) ( 9.2 ) ( 9.3 ) ( 8.3 ) .", "label": "", "metadata": {}, "score": "95.37198"}
{"text": "Current transfer receipts ............................ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 .Total current receipts ............................. 16.8 14.4 14.9 18.6 18.3 18.2 17.1 16.8 17.4 .", "label": "", "metadata": {}, "score": "95.4621"}
{"text": "Branch , Terra ....... 27 47 1.7 .FOULOUTS G No .Gardner , Nadirah .... 26 3 .Reynolds , Brittany .Wiltz , Whitley ...... 26 2 .", "label": "", "metadata": {}, "score": "95.46707"}
{"text": "Current tax receipts ................................. 10.9 11.0 10.7 11.5 11.1 11.5 11.0 10.7 10.4 .Personal current taxes .............................( 7.7 ) ( 8.0 ) ( 7.8 ) ( 8.4 ) ( 7.9 ) ( 8.3 ) ( 8.0 ) ( 7.8 ) ( 7.5 ) .", "label": "", "metadata": {}, "score": "95.584564"}
{"text": "Social Security Administration ( Off - budget ) ..................... 20.5 20.1 20.4 20.4 20.9 21.6 22.0 23.6 .Other Independent Agencies ( On - budget ) .......................... 0.7 0.5 0.6 0.6 0.5 0.5 0.5 0.6 .", "label": "", "metadata": {}, "score": "95.67391"}
{"text": "Small Business Administration ........................ 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 .Social Security Administration ( On - budget ) ........... ......... ......... ......... ......... ......... 0.1 0.1 0.2 0.2 .", "label": "", "metadata": {}, "score": "95.70502"}
{"text": "( 2.6 ) ( 2.8 ) ( 2.8 ) ( 2.9 ) ( 2.6 ) ( 2.6 ) ( 2.4 ) ( 2.1 ) ( 2.1 ) .", "label": "", "metadata": {}, "score": "95.77556"}
{"text": "Social Security Administration ( On - budget ) ........... 0.2 0.2 0.2 1.0 1.6 1.5 1.3 1.5 1.4 .Social Security Administration ( Off - budget ) .......... 16.8 17.2 19.8 20.6 19.3 19.7 20.6 20.6 20.3 .", "label": "", "metadata": {}, "score": "95.846245"}
{"text": "Total ............... 659 - 1767 .373104 - 400 .260 336 - 513 .655 1758 65.1 461 - 1281 .360 72 - 294 .245 259 - 387 .669 1253 62.7 .", "label": "", "metadata": {}, "score": "95.93176"}
{"text": "Home games - Avg / Game .... 13 - 299 13 - 389 .Neutral site - Avg / Game .SCORE BY PERIODS : 1st 2nd Total .", "label": "", "metadata": {}, "score": "95.97505"}
{"text": "Current tax receipts ................................. 15.0 13.9 14.2 14.7 14.1 14.4 14.2 13.9 13.4 .Personal current taxes .............................( 7.8 ) ( 7.6 ) ( 7.5 ) ( 7.9 ) ( 7.9 ) ( 8.0 ) ( 7.9 ) ( 7.5 ) ( 7.1 ) .", "label": "", "metadata": {}, "score": "96.176285"}
{"text": "Corbett , Clarissa ...33 - 89 .371 7 - 20 .350 25 - 47 .53298 3.8 23 - 58 .397 5 - 14 .357 20 - 35 .571", "label": "", "metadata": {}, "score": "96.21953"}
{"text": "Government social benefits .........................( 7.6 ) ( 8.0 ) ( 7.6 ) ( 7.2 ) ( 7.1 ) ( 7.7 ) ( 8.0 ) ( 8.4 ) ( 8.9 ) .", "label": "", "metadata": {}, "score": "96.25972"}
{"text": "( 0.2 ) ( 0.3 ) ( 0.3 ) ( 0.2 ) ( 0.2 ) ( 0.2 ) ( 0.2 ) ( -0.5 ) ( 0.2 ) .", "label": "", "metadata": {}, "score": "96.28325"}
{"text": "( 1.0 ) ( 1.1 ) ( 1.1 ) ( 0.9 ) ( 0.9 ) ( 0.9 ) ( 0.9 ) ( 0.9 ) .Taxes on corporate income ..................................... ( 2.0 ) ( 2.2 ) ( 2.4 ) ( 2.4 ) ( 2.4 ) ( 2.4 ) ( 2.3 ) ( 2.3 ) .", "label": "", "metadata": {}, "score": "96.29375"}
{"text": "( 0.4 ) ( 0.2 ) ( 0.2 ) ( 0.2 ) ( 0.2 ) ( 0.2 ) ( 0.2 ) ( 0.2 ) ( 0.2 ) .", "label": "", "metadata": {}, "score": "96.342155"}
{"text": "( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) .", "label": "", "metadata": {}, "score": "96.43329"}
{"text": "Current Receipts .Current tax receipts ............................................ 12.6 10.5 9.9 9.7 10.8 11.7 11.9 11.8 .Personal current taxes ........................................( 9.9 ) ( 8.2 ) ( 7.2 ) ( 6.8 ) ( 7.4 ) ( 7.9 ) ( 8.4 ) ( 8.5 ) .", "label": "", "metadata": {}, "score": "96.43944"}
{"text": "Current Expenditures .Consumption expenditures ........................................ 6.8 6.3 6.0 5.7 5.6 5.2 5.1 5.1 .Defense .......................................................( 4.7 ) ( 4.4 ) ( 4.1 ) ( 3.8 ) ( 3.7 ) ( 3.5 ) ( 3.4 ) ( 3.3 ) .", "label": "", "metadata": {}, "score": "96.48511"}
{"text": "061002 G92 0.0 0.0 061009 585 0.4- 0.7 + 061021 G92 ( 2.1- 1.5 + ) .061002 G92 1.2 + 1.0- 061009585 0.3- 0.9- 061021 G92 ( 4.6- 2.7 + ) .", "label": "", "metadata": {}, "score": "96.50018"}
{"text": "Current tax receipts ................................. 14.8 12.6 13.0 16.7 16.3 16.3 15.1 14.6 15.1 .Personal current taxes .............................( 7.4 ) ( 5.7 ) ( 5.8 ) ( 7.0 ) ( 8.0 ) ( 8.2 ) ( 7.8 ) ( 7.3 ) ( 7.6 ) .", "label": "", "metadata": {}, "score": "96.69549"}
{"text": "Current expenditures ................................. 16.7 18.2 19.0 18.8 19.0 19.6 19.7 19.5 19.0 .Net investment : .Gross government investment ........................ 2.0 2.2 2.0 1.6 1.4 1.2 1.0 1.0 1.0 .", "label": "", "metadata": {}, "score": "96.77652"}
{"text": "44 Sharp , Jamilah P SR Y M.P.E.C. 2011-Y07 Issued 2011 Dec. 18 , 04:46 UT The Minor Planet Electronic Circulars contain information on unusual minor planets and routine data on comets .", "label": "", "metadata": {}, "score": "96.85329"}
{"text": "Gardner , Nadirah .... 116 - 305 .380 12 - 57 .211 56 - 79 .709 300 11.5 92 - 245 .376 10 - 44 .227 49 - 67 .731 243 12.2 .", "label": "", "metadata": {}, "score": "96.90442"}
{"text": "Current transfer receipts ............................ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 .Total current receipts .............................17.4 16.4 16.8 17.8 17.4 17.9 17.9 17.6 17.0 .", "label": "", "metadata": {}, "score": "97.06325"}
{"text": "Branch , Terra ....... 27 406 14 17 31 28 0 18 47 0.4 13 .Elkins , Sylvia ......17 93 5 4 9 7 0 6 7 0.9 3 .", "label": "", "metadata": {}, "score": "97.12829"}
{"text": "Nondefense ......................................... ( 2.1 ) ( 2.1 ) ( 2.0 ) ( 2.1 ) ( 2.1 ) ( 2.1 ) ( 2.3 ) ( 2.2 ) ( 2.1 ) .", "label": "", "metadata": {}, "score": "97.37632"}
{"text": "H06 0.9 + 0.2- 061118 232 1.3 + 0.9- .061006J63 0.9- 1.1- 061016 693 ( 1.5 + 0.5- ) 061118232 1.1 + 0.8- . 061006 372 0.3 + 1.0 + 061016 693 ( 1.5 + 0.3- ) 061118 J95 ( 4.0 + 0.8- ) .", "label": "", "metadata": {}, "score": "97.392715"}
{"text": ", Dow 30 +14.2 % ; S&P 500 +13.4 % ; Russell 2000 +13 % ; NDQ 100 +11.1 % , Nasdaq Composite +10.7 % .", "label": "", "metadata": {}, "score": "97.44997"}
{"text": "Net Lending or Borrowing ( - ) .......................N / A N / A N / A N / A N / A N / A N / A N / A N / A .", "label": "", "metadata": {}, "score": "97.45125"}
{"text": "PK11Y010 KC2011 12 17.89481 23 08 20.80 +26 40 44.3 19.9 TuEY007J95 .PK11Y010 KC2011 12 17.90097 23 08 22.15 +26 40 36.3 18.1 TwEY007J77 .", "label": "", "metadata": {}, "score": "97.58539"}
{"text": "061003 G92 0.3 + 1.2 + 061013 448 0.4 + 0.4- 061027H06 1.2- 0.2 + .061003 G92 0.1 + 0.7 + 061014 349 0.9 + 0.2- 061027 H06 ( 1.7- 1.0 + ) .", "label": "", "metadata": {}, "score": "97.60829"}
{"text": "Defense ..........................................( N / A ) ( N / A ) ( N / A ) ( -1.9 ) ( -1.9 ) ( -1.8 ) ( -1.8 ) ( -1.7 ) ( -1.6 ) .", "label": "", "metadata": {}, "score": "97.62402"}
{"text": "061003 J77 0.6 + 0.2- 061012 J95 0.1- 0.1- 061022 G92 1.3- 1.4 + .061003 J77 0.9 + 1.0- 061012 J95 0.4- 0.4 + 061022 G92 ( 2.5- 0.2 + ) .", "label": "", "metadata": {}, "score": "97.63128"}
{"text": "061003 J95 0.0 0.1- 061011 H06 0.6- 0.3- 061021 361 ( 1.9 + 2.6- ) .061003 J95 0.1- 0.1- 061011 673 ( 2.3 + 0.5- ) 061022", "label": "", "metadata": {}, "score": "97.71172"}
{"text": "Current Receipts .Current tax receipts ................................. 13.3 13.2 13.6 14.9 14.0 12.5 12.6 12.4 12.6 .Personal current taxes ............................. ( 7.2 ) ( 7.6 ) ( 7.9 ) ( 9.2 ) ( 8.9 ) ( 7.8 ) ( 8.1 ) ( 7.8 ) ( 8.2 ) .", "label": "", "metadata": {}, "score": "97.71782"}
{"text": "061003 G92 0.3 + 1.0 + 061013 448 0.1 + 0.2- 061027 J95 1.1- 0.8 + .061003 G92 0.5 + 0.4 + 061013 448 0.7 + 0.6- 061027 J95 0.7- 0.2 + .", "label": "", "metadata": {}, "score": "97.79466"}
{"text": "061003 J77 0.9 + 0.3- 061012 939 ( 4.9 + 0.9- ) 061023 442 0.1 + 0.4- .061003 J77 0.4- 0.1 + 061012 939 ( 0.7 + 2.4 + ) 061023 442 ( 2.8- 0.4- ) .", "label": "", "metadata": {}, "score": "97.80627"}
{"text": "That is what we now have and it is killing us .Meanwhile , think what you want - it does n't matter as the corporations and lobbies are getting their way in the absence of any other grass roots action .", "label": "", "metadata": {}, "score": "97.991394"}
{"text": "061009379 0.1 + 1.0- 061021 G96 0.6 + 0.5- .061003 J95 0.4 + 0.0 061009 379 ( 0.9 + 1.7- ) 061021 448 0.2- 0.3- .", "label": "", "metadata": {}, "score": "98.12099"}
{"text": "Total .............. 27 5400 659 - 1767 .373104 - 400 .260 336 - 513 .655513 697 1210 44.8 522 10 275 599 69 271 1758 65.1 .", "label": "", "metadata": {}, "score": "98.19647"}
{"text": "J95 0.1- 0.0 061015 461 1.1 + 0.4- 061031 372 ( 2.3- 0.2- ) .061004J95 0.1- 0.2 + 061015 461 1.2 + 0.4- 061031 372 ( 2.8- 0.9 + ) .", "label": "", "metadata": {}, "score": "98.203705"}
{"text": "Current expenditures ............................................ 22.6 21.8 21.8 21.3 20.7 20.0 19.4 19.1 .Net investment : .Gross government investment ................................... 1.3 1.1 1.1 1.1 0.9 0.9 0.9 0.8 .", "label": "", "metadata": {}, "score": "98.557556"}
{"text": "Nondefense .................................................. ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.4 ) ( 0.3 ) ( 0.3 ) ( 0.4 ) ( 0.3 ) .", "label": "", "metadata": {}, "score": "98.5956"}
{"text": "Addendum : Total Receipts and Expenditures .Current receipts ..................................... N / A N / A N / A N / A N / A N / A N / A N / A N / A .", "label": "", "metadata": {}, "score": "98.651024"}
{"text": "Gold closed little changed in a very narrow inside trading range ( ? ) , leaving Friday 's high of $ 1487.20 , highest since 4/12 , out to dry and closed at $ 1468.00 -$1.50 .", "label": "", "metadata": {}, "score": "98.69293"}
{"text": "Current expenditures ............................................ 19.4 19.9 20.5 20.4 20.5 20.6 20.9 20.7 .Net investment : .Gross government investment ................................... 0.8 0.8 0.9 0.9 0.9 0.9 0.9 0.8 .", "label": "", "metadata": {}, "score": "98.76439"}
{"text": "379 1.2 + 0.1- 061124 G92 ( 5.3 + 0.8- ) .061007300 1.2- 1.0 + 061019 G92 ( 0.7- 4.6 + ) 061124 G92 ( 1.2 + 2.5 + ) .", "label": "", "metadata": {}, "score": "98.77153"}
{"text": "RECORD : OVERALL HOME AWAY NEUTRAL .ALL GAMES ...........( 8 - 19 ) ( 4 - 9 ) ( 3 - 10 ) ( 1 - 0 ) .", "label": "", "metadata": {}, "score": "98.853935"}
{"text": "4.3 1.1 38 15 11.2 . 10 Pullen , Cherelle .... 26 - 1 9.2 .179 .136 1.000 1.3 0.8 17 0 0.9 .11 Corbett , Clarissa ... 26 - 2 12.8 .371 .350 .532", "label": "", "metadata": {}, "score": "98.90264"}
{"text": "Defense ..........................................( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) ( N / A ) .", "label": "", "metadata": {}, "score": "98.921814"}
{"text": "Capital transfer payments ............................ 0.6 0.5 0.6 0.6 0.6 0.5 0.5 0.5 0.5 .Total expenditures ................................. 17.7 19.1 19.9 19.4 19.4 19.8 19.8 19.5 18.9 .", "label": "", "metadata": {}, "score": "99.20889"}
{"text": "061008367 0.3- 0.4 + 061020 372 0.2- 0.4- 111217 J95 1.0 + 0.0 . 061008367 0.9- 0.2 + 061020 349 0.1 + 0.2 + 111217 J77 ( 4.8 + 0.2 + ) .", "label": "", "metadata": {}, "score": "99.3038"}
{"text": "Consumption expenditures .............................10.4 10.9 10.3 9.6 9.7 9.6 9.8 9.8 9.1 .Defense ............................................ ( 9.1 ) ( 9.5 ) ( 8.5 ) ( 7.8 ) ( 8.0 ) ( 7.9 ) ( 7.8 ) ( 7.7 ) ( 7.0 ) .", "label": "", "metadata": {}, "score": "99.32199"}
{"text": "061003 G92 0.2- 0.3 + 061015 118 1.2 + 0.6- 061029 H06 ( 2.0- 1.1 + ) .061003 G92 0.5 + 0.0 061015 118 1.2 + 0.7- 061029 H06 0.3- 0.2- .", "label": "", "metadata": {}, "score": "99.34369"}
{"text": "Capital transfer payments ............................ 0.5 0.6 0.6 0.5 0.5 0.6 0.5 0.5 0.4 .Total expenditures ................................. 21.0 21.3 20.8 20.3 20.0 21.3 21.9 23.1 24.0 .", "label": "", "metadata": {}, "score": "99.40092"}
{"text": "SCORING FG - FGA FG% 3FG - FGA 3PT% FT - FTA FT% PTS PTS / G FG - FGA FG% 3FG - FGA 3PT% FT - FTA FT% PTS PTS / G .", "label": "", "metadata": {}, "score": "99.44948"}
{"text": "11/22/08 2:00 pm FLORIDA SOUTHERN 67 - 79 L 172 ( 16)Reynolds , Brittany ( 16)Sharp , Jamilah .11/25/08 6:00 pm TOCCOA FALLS W 95 - 48 102 ( 17)Burris , Brandi ( 9)Wiltz , Whitley .", "label": "", "metadata": {}, "score": "99.471176"}
{"text": "Corbett , Clarissa ... 26 - 2 12.8 .371 .350 .5321.7 1.1 17 4 3.8 19 - 1 13.2 .397 .357 .571 1.4 1.1 10 4 3.7 .", "label": "", "metadata": {}, "score": "99.511154"}
{"text": "Nondefense .................................................. ( 0.3 ) ( 0.3 ) ( 0.3 ) ( 0.3 ) ( 0.3 ) ( 0.3 ) ( 0.3 ) ( 0.3 ) .", "label": "", "metadata": {}, "score": "99.6127"}
{"text": "Total receipts ..................................... N / A N / A N / A 18.1 17.8 18.2 18.3 18.0 17.4 .Current expenditures ................................. N / A N / A N / A 16.4 17.1 17.0 17.3 17.1 16.3 .", "label": "", "metadata": {}, "score": "99.7552"}
{"text": "Subsidies ............................................ 0.2 0.3 0.3 0.4 0.3 0.2 0.2 0.2 0.2 .Total current expenditures ......................... 14.4 15.7 16.3 14.0 16.7 17.7 17.4 16.1 15.7 .", "label": "", "metadata": {}, "score": "99.837685"}
{"text": "Sharp , Jamilah ...... 27 - 27 26.4 .414 .167 .564 7.0 0.5 14 7 7.3 20 - 20 26.4 .439 .200 .556 7.0 0.6 11 4 7.3 .", "label": "", "metadata": {}, "score": "100.04577"}
{"text": "Total receipts ..................................... N / A N / A N / A N / A N / A N / A N / A N / A N / A .", "label": "", "metadata": {}, "score": "100.09392"}
{"text": "Total current receipts ............................. 17.6 17.5 18.0 18.3 18.9 19.0 19.7 19.3 18.2 .Current Expenditures .Consumption expenditures ............................. 8.0 7.7 7.5 7.2 7.0 7.3 7.6 8.0 8.3 .", "label": "", "metadata": {}, "score": "100.11955"}
{"text": "Defense .......................................... ( -1.0 ) ( -0.9 ) ( -0.9 ) ( -0.9 ) ( -0.8 ) ( -0.8 ) ( -0.8 ) ( -0.9 ) ( -0.9 ) .", "label": "", "metadata": {}, "score": "100.28894"}
{"text": "061003 J77 0.4- 0.1 + 061012 850 0.6- 0.2- 061023 H06 0.2 + 0.5 + .061003 J77 0.9- 0.3 + 061012 850 0.7- 0.4 + 061023 372 ( 1.7- 0.0 ) .", "label": "", "metadata": {}, "score": "100.31797"}
{"text": "Interest payments ............................................... 2.7 2.3 2.0 1.9 2.0 2.2 2.2 2.3 .Subsidies ....................................................... 0.5 0.4 0.4 0.4 0.4 0.4 0.3 0.3 .Total current expenditures .................................... 19.4 19.9 20.5 20.4 20.5 20.6 20.9 20.7 .", "label": "", "metadata": {}, "score": "100.37457"}
{"text": "Consumption expenditures ............................. 7.8 8.6 8.2 8.2 11.4 12.8 12.3 10.8 10.6 .Defense ............................................ ( 6.4 ) ( 6.3 ) ( 5.9 ) ( 7.1 ) ( 10.1 ) ( 11.1 ) ( 10.5 ) ( 9.1 ) ( 8.9 ) .", "label": "", "metadata": {}, "score": "100.41492"}
{"text": "Elkins , Sylvia ...... 17 - 1 5.5 .222 .200 .500 0.5 0.4 3 0 1.1 11 - 1 5.5 .176 .214 .500 0.6 0.5 0 0 0.9 .", "label": "", "metadata": {}, "score": "100.42773"}
{"text": "Defense ..................................................... ( -0.9 ) ( -0.9 ) ( -0.8 ) ( -0.8 ) ( -0.7 ) ( -0.7 ) ( -0.7 ) ( -0.6 ) .", "label": "", "metadata": {}, "score": "100.54404"}
{"text": "23 James , Monica ...... 12 - 1 61 5.1 5 - 23 .217 0 - 6 .000 2 - 6 .333 2 2 4 0.3 0 0 3 5 0 2 12 1.0 .", "label": "", "metadata": {}, "score": "100.58682"}
{"text": "( 0.4 ) ( 0.4 ) ( 0.6 ) ( 0.7 ) ( 0.7 ) ( 0.6 ) ( 0.6 ) ( 0.5 ) ( 0.5 ) .", "label": "", "metadata": {}, "score": "100.84955"}
{"text": "( 10)Wiltz , Whitley .12/30/08 7 p.m. at Valdosta State 51 - 68 L 310 ( 10)Gardner , Nadirah ( 9)Burris , Brandi .( 10)Burris , Brandi .", "label": "", "metadata": {}, "score": "100.95601"}
{"text": "4.0 2.0 51 5 11.5 20 - 19 26.2 .376 .227 .731 4.0 1.9 36 3 12.2 .James , Monica ....... 12 - 1 5.1 .217 .000 .333 0.3 0.3 2 0 1.0 7 - 1 4.0 .167 .000 .333 0.3 0.3 1 0 0.6 .", "label": "", "metadata": {}, "score": "100.958176"}
{"text": "Subsidies ............................................ 0.2 0.3 0.3 0.4 0.4 0.3 0.4 0.4 0.5 .Total current expenditures ......................... 20.6 20.8 20.2 19.8 19.4 20.6 21.4 22.5 23.4 .", "label": "", "metadata": {}, "score": "101.06409"}
{"text": "Defense ..................................................... ( -0.6 ) ( -0.6 ) ( -0.6 ) ( -0.6 ) ( -0.5 ) ( -0.5 ) ( -0.5 ) ( -0.5 ) .", "label": "", "metadata": {}, "score": "101.09874"}
{"text": "Decl .Delta r Elong .Phase m1 m2 .2012 01 17 01 34 56.3 +06 52 01 0.2482 1.0079 88.4 77.3 17.0 Gareth V. Williams ( C ) Copyright 2011 MPC M.P.E.C. 2011-Y07 The ' fix ' is in !", "label": "", "metadata": {}, "score": "101.2827"}
{"text": "Taxes on corporate income .......................... ( 4.6 ) ( 3.9 ) ( 4.4 ) ( 4.3 ) ( 3.8 ) ( 4.0 ) ( 3.9 ) ( 4.0 ) ( 4.0 ) .", "label": "", "metadata": {}, "score": "101.30693"}
{"text": "Interest payments ............................................... 3.8 3.7 3.9 3.8 3.7 3.5 3.1 2.9 .Subsidies ....................................................... 0.6 0.4 0.5 0.4 0.4 0.4 0.4 0.5 .Total current expenditures .................................... 22.6 21.8 21.8 21.3 20.7 20.0 19.4 19.1 .", "label": "", "metadata": {}, "score": "101.3212"}
{"text": "20 Wiltz , Whitley ...... 26 - 23 28.0 .368 .316 .667 6.7 1.2 39 11 7.5 .22 Gardner , Nadirah .... 26 - 25 25.8 .380 .211 .709", "label": "", "metadata": {}, "score": "101.36174"}
{"text": "Capital transfer payments ............................ 0.4 0.5 0.5 0.4 0.4 0.4 0.4 0.4 0.3 .Total expenditures ................................. 22.9 23.5 23.6 23.2 22.3 22.0 22.2 22.4 23.3 .", "label": "", "metadata": {}, "score": "101.403015"}
{"text": "Elkins , Sylvia ...... 4 20 .200 Burris , Brandi ...... 26 23 0.9 .Hadley , Arile ....... 2 11 .182Branch , Terra ....... 27 19 0.7 .", "label": "", "metadata": {}, "score": "101.53839"}
{"text": "U.S. stock futures higher in another narrow trading range : DOW +38 ; SPX +3.10 ; NDQ +6.75 .Bonds were totally destroyed on Friday and slid lower yesterday , continuing overnight .", "label": "", "metadata": {}, "score": "101.58979"}
{"text": "Branch , Terra ....... 1417 31 28 0 18 47 0.4 13 11 10 21 22 0 13 41 0.3 13 .Elkins , Sylvia ...... 5 4 9 7 0 6 7 0.9 3 3 4 7 5 0 5 7 0.7 3 .", "label": "", "metadata": {}, "score": "101.705124"}
{"text": "Blocks per game ........ 2.6 3.2 .WINNING STREAK ........... 1 - .Home win streak ........ 1 - .ATTENDANCE ............... 3892 5131 .Home games - Avg / Game .... 13 - 299 13 - 389 .", "label": "", "metadata": {}, "score": "101.81311"}
{"text": "3-point FG pct ......... .260 .293 .3-pt FG made per game .FREE THROWS - ATT .......... 336 - 513 398 - 610 .", "label": "", "metadata": {}, "score": "101.87947"}
{"text": "Subsidies ............................................ 0.4 0.5 0.4 0.4 0.4 0.5 0.4 0.5 0.3 .Total current expenditures ......................... 16.7 18.2 19.0 18.8 19.0 19.6 19.7 19.5 19.0 .", "label": "", "metadata": {}, "score": "101.96561"}
{"text": "Would they have advocated weapons of the power there is today ? ... especially now that we have a standing army to defend us .Highly unlikely ... keep that in mind you strict constructionists !", "label": "", "metadata": {}, "score": "101.99559"}
{"text": "32 Smith , Brittany ..... 8 - 0 4.6 .333 .000 .333 1.4 0.4 4 0 1.0 .33 Hadley , Arile ....... 27 - 3 16.6 .391 .182 .704 4.3 0.3 15 13 3.3 .", "label": "", "metadata": {}, "score": "102.15242"}
{"text": "Defense .......................................... ( -0.9 ) ( -0.9 ) ( -0.9 ) ( -0.9 ) ( -0.9 ) ( -0.9 ) ( -0.9 ) ( -0.9 ) ( -0.9 ) .", "label": "", "metadata": {}, "score": "102.15935"}
{"text": "Net Federal Government Saving ...................... 1.4 -0.6 -0.1 1.4 0.4 0.9 0.7 0.5 0.7 .Addendum : Total Receipts and Expenditures .Current receipts ..................................... N / A N / A N / A 17.8 17.4 17.9 17.9 17.6 17.0 .", "label": "", "metadata": {}, "score": "102.163704"}
{"text": "J95 0.4- 0.2 + 061017 048 0.8 + 0.9- 061122 850 ( 1.6 + 0.2- ) .061007J95 0.5- 0.1- 061017 G92 ( 2.9- 1.4 + ) 061123 850 ( 2.2 + 0.9- ) .", "label": "", "metadata": {}, "score": "102.18091"}
{"text": "Total ............... 27 .373 .260 .65544.8 10.2 271 69 65.1 .Opponents ........... 27 .423 .293 .65238.4 14.1 275 87 69.4 .SCORING GP FG - FGA FG% 3FG - FGA 3PT% FT - FTA FT% PTS PTS / G .", "label": "", "metadata": {}, "score": "102.218"}
{"text": "Taxes on corporate income ..........................( 4.1 ) ( 3.8 ) ( 3.8 ) ( 3.9 ) ( 3.3 ) ( 3.0 ) ( 2.9 ) ( 3.1 ) ( 3.0 ) .", "label": "", "metadata": {}, "score": "102.344124"}
{"text": "Current transfer receipts ....................................... 0.3 0.2 0.2 0.2 0.1 0.3 0.2 0.3 .Total current receipts ........................................20.2 18.0 17.2 17.0 17.9 18.9 19.2 19.1 .", "label": "", "metadata": {}, "score": "102.420555"}
{"text": "Gross government investment ........................ N / A N / A N / A 2.8 2.9 3.0 2.8 2.5 2.2 .Defense ..........................................( N / A ) ( N / A ) ( N / A ) ( 2.5 ) ( 2.5 ) ( 2.5 ) ( 2.3 ) ( 1.9 ) ( 1.6 ) .", "label": "", "metadata": {}, "score": "102.43152"}
{"text": "Taxes on corporate income .......................... ( 4.4 ) ( 4.0 ) ( 4.3 ) ( 6.8 ) ( 5.6 ) ( 5.3 ) ( 4.6 ) ( 4.8 ) ( 5.0 ) .", "label": "", "metadata": {}, "score": "102.449715"}
{"text": "TEAM STATISTICS GSWW OPP .SCORING .................. 1758 1875 .Points per game ........ 65.1 69.4 .Scoring margin ......... -4.3 - .FIELD GOALS - ATT .......... 659 - 1767 673 - 1590 .", "label": "", "metadata": {}, "score": "102.637474"}
{"text": "Capital transfer payments ....................................... 0.4 0.4 0.6 0.5 0.5 0.5 0.6 0.5 .Total expenditures ............................................ 19.7 20.3 21.1 21.0 21.1 21.2 21.5 21.2 .Net Lending or Borrowing ( - ) .................................. 0.7 -2.1 -3.7 -3.8 -3.0 -2.0 -2.1 -2.0 .", "label": "", "metadata": {}, "score": "102.64383"}
{"text": "PK11Y010 KC2011 12 17.93102 23 08 27.02 +26 39 53.3 wEY007J77 .Observer details : 595 Farra d'Isonzo .Observer E. Pettarin . 0.40-m f/4.5 reflector + CCD .", "label": "", "metadata": {}, "score": "102.95085"}
{"text": "Education ....................................................... 1.9 1.9 1.8 1.9 1.9 2.3 2.6 2.7 .Energy .......................................................... 0.9 0.9 0.9 0.8 0.9 0.9 0.9 0.9 .Health and Human Services ....................................... 21.2 21.2 21.1 21.4 22.9 23.1 23.4 23.7 .", "label": "", "metadata": {}, "score": "103.00306"}
{"text": "Burris , Brandi ...... 26 106 - 260 .408 23 - 83 .27756 - 73 .767291 11.2 .Pullen , Cherelle .... 26 7 - 39 .179 3 - 22 .136 6 - 6 1.000 23 0.9 .", "label": "", "metadata": {}, "score": "103.07272"}
{"text": "Capital transfer payments ....................................... 0.4 0.4 0.4 0.4 0.4 0.3 0.3 0.4 .Total expenditures ............................................ 23.1 22.2 22.1 21.6 20.8 20.2 19.6 19.4 .Net Lending or Borrowing ( - ) .................................. -4.6 -3.3 -2.8 -2.0 -0.7 0.4 0.9 1.9 .", "label": "", "metadata": {}, "score": "103.10179"}
{"text": "Sharp , Jamilah ...... 27 82 - 198 .414 3 - 18 .167 31 - 55 .564 198 7.3 .Total ............... 27 659 - 1767 .373", "label": "", "metadata": {}, "score": "103.10768"}
{"text": "Subsidies ............................................ 0.6 0.5 0.5 0.6 0.5 0.5 0.5 0.4 0.4 .Total current expenditures ......................... 22.1 22.5 22.5 22.1 21.5 21.3 21.5 21.7 22.7 .", "label": "", "metadata": {}, "score": "103.193756"}
{"text": "SCORE BY PERIODS : 1st 2nd Total .Georgia Southwestern .......... 838 920 - 1758 .Opponents ..................... 885 990 - 1875 .Georgia Southwestern Category Leaders ( as of Feb 28 , 2009 ) .", "label": "", "metadata": {}, "score": "103.32209"}
{"text": "Education ............................................ 1.7 1.9 1.8 1.9 1.9 2.1 1.7 2.1 1.9 .Energy ............................................... 1.0 1.0 1.0 0.9 1.1 1.2 1.2 1.2 1.0 .Health and Human Services ............................ 13.2 13.3 14.0 15.0 16.8 18.0 19.1 20.0 20.5 .", "label": "", "metadata": {}, "score": "103.39554"}
{"text": "22 Gardner , Nadirah PG SO Y .23 James , Monica G SR Y .25 Thomas , Krystal F JR Y .32 Smith , Brittany P SR Y .", "label": "", "metadata": {}, "score": "103.64344"}
{"text": "Points per game ........ 65.1 69.4 .Scoring margin ......... -4.3 - .FIELD GOALS - ATT .......... 659 - 1767 673 - 1590 .Field goal pct ......... .373 .423 .", "label": "", "metadata": {}, "score": "103.64721"}
{"text": "Gardner , Nadirah .... 116 305 .380Wiltz , Whitley ...... 26 193 7.4 .Corbett , Clarissa ... 33 89 .371 .Branch , Terra ....... 61 165 .370", "label": "", "metadata": {}, "score": "103.792404"}
{"text": "17 18 1.1 .Elkins , Sylvia ......17 18 1.1 Smith , Brittany ..... 8 8 1.0 .James , Monica ....... 12 12 1.0 James , Monica ....... 12 12 1.0 . . .", "label": "", "metadata": {}, "score": "103.82063"}
{"text": "Gross government investment ........................ 1.1 1.2 1.2 1.2 1.2 1.3 1.3 1.4 1.6 .Defense ..........................................( 0.7 ) ( 0.9 ) ( 0.9 ) ( 0.8 ) ( 0.8 ) ( 0.9 ) ( 0.9 ) ( 1.0 ) ( 1.2 ) .", "label": "", "metadata": {}, "score": "103.923386"}
{"text": "061003 G92 0.2 + 0.2 + 061014 349 1.0 + 0.3- 061027 448 0.0 0.3- .061003 G92 0.5- 0.5- 061014 D70 1.2 + 0.6- 061027 448 0.4- 0.0 . 061003 G92 0.1- 1.0- 061014 D70 ( 1.8 + 0.3 + ) 061028 118 1.3- 0.5 + .", "label": "", "metadata": {}, "score": "103.948456"}
{"text": "FG PERCENTAGE FG ATT Pct FIELD GOAL ATTEMPTS G Att Att / G .Sharp , Jamilah ...... 82 198 .414Gardner , Nadirah .... 26 305 11.7 .", "label": "", "metadata": {}, "score": "104.05698"}
{"text": "Free throw pct ......... .655 .652 .REBOUNDS ................. 1210 1038 .Rebounds per game ......44.8 38.4 .Rebounding margin ......+6.4 - .ASSISTS .................. 275 381 .", "label": "", "metadata": {}, "score": "104.144745"}
{"text": "Taxes on corporate income ..........................( 2.7 ) ( 3.0 ) ( 3.0 ) ( 3.0 ) ( 3.0 ) ( 2.6 ) ( 2.2 ) ( 1.6 ) ( 1.6 ) .", "label": "", "metadata": {}, "score": "104.32067"}
{"text": "# # Player Name Pos Year Miscellaneous Information Actv . 3 Billings , Tiandra G FR Y .4 Burris , Brandi G JR Y .", "label": "", "metadata": {}, "score": "104.32239"}
{"text": "Addendum : Total Receipts and Expenditures .Current receipts ................................................ 18.3 18.7 19.1 19.4 19.9 20.3 20.3 21.0 .Capital transfer receipts ....................................... 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 .", "label": "", "metadata": {}, "score": "104.36489"}
{"text": "349 0.6- 0.6 + 061020 G92 ( 3.5- 1.3 + ) 111217 595 0.2 + 0.5 + .061008349 0.4- 0.7 + 061020 372 0.1 + 0.5- 111217 J95 0.2- 0.1 + . 061008", "label": "", "metadata": {}, "score": "104.60002"}
{"text": "Burris , Brandi ...... 106 - 260 .408 23 - 83 .27756 - 73 .767291 11.2 75 - 201 .373 13 - 63 .206 51 - 64 .797 214 10.7 .", "label": "", "metadata": {}, "score": "104.63806"}
{"text": "Burris , Brandi ...... 26 719 37 75 112 72 2 29 86 0.3 19 .Pullen , Cherelle .... 26 240 6 27 33 21 0 21 27 0.8 8 .", "label": "", "metadata": {}, "score": "104.64385"}
{"text": "Dow Transports which rose 79 points 1.3 % - for honors AND a 100 point trading range , and yep a new high of 6314 ... eclipsing the 3/19 high by all of 23 points ... wake up , investors , you have been had ... again !", "label": "", "metadata": {}, "score": "104.64468"}
{"text": "Instead of starting a new business with 3 - 4 employees , why not just go to the internet and to hell with your local economy .", "label": "", "metadata": {}, "score": "104.65096"}
{"text": "Consumption expenditures ........................................ 5.2 5.5 6.0 6.1 6.2 6.2 6.3 6.2 .Defense .......................................................( 3.3 ) ( 3.5 ) ( 3.9 ) ( 4.1 ) ( 4.1 ) ( 4.1 ) ( 4.2 ) ( 4.3 ) .", "label": "", "metadata": {}, "score": "104.7805"}
{"text": "Education ............................................ 2.4 2.5 2.5 2.0 1.8 1.8 1.8 1.8 1.7 .Energy ............................................... 1.5 1.2 1.7 1.6 1.3 1.3 1.1 1.1 1.1 .Health and Human Services ............................ 11.5 11.6 11.9 11.9 11.8 12.0 12.1 12.4 13.1 .", "label": "", "metadata": {}, "score": "104.8212"}
{"text": "vs -0.8 % vs -0.4 % ; Hang Seng +0.6 % vs +1 % ! vs +0.1 % vs -0.3 % vs +0.7 % ; Korea DOWN 0.4 % vs -0.2 % vs +0.4 % vs -0.3 % vs closed ; India +1.1 % ! vs +0.5 % vs -0.8 % vs +1.2 % ! ! !", "label": "", "metadata": {}, "score": "104.88316"}
{"text": "Burris , Brandi ...... 26 - 25 27.7 .408 .277 .7674.3 1.1 38 15 11.2 20 - 19 27.4 .373 .206 .797 4.3 1.2 26 10 10.7 .", "label": "", "metadata": {}, "score": "104.95418"}
{"text": "Addendum : Total Receipts and Expenditures .Current receipts .....................................17.1 17.6 18.0 19.6 18.7 17.3 17.5 17.8 18.3 .Capital transfer receipts ............................ 0.4 0.4 0.4 0.4 0.4 0.3 0.5 0.4 0.3 .", "label": "", "metadata": {}, "score": "104.96234"}
{"text": "Researchers found coated stents ... read more Georgia Southwestern Season Schedule / Results & Leaders ( as of Feb 28 , 2009 ) .All games .", "label": "", "metadata": {}, "score": "105.01102"}
{"text": "Addendum : Total Receipts and Expenditures .Current receipts ..................................... 18.1 18.4 18.2 19.0 18.8 19.1 18.5 18.5 18.1 .Capital transfer receipts ............................ 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 .", "label": "", "metadata": {}, "score": "105.06119"}
{"text": "061003 H06 0.8 + 0.4 + 061013 J63 ( 0.2 + 2.6- ) 061025 442 ( 2.9- 0.4 + ) .061003 H06 0.0 0.1 + 061013 850 0.2 + 0.3 + 061025 H06 1.4- 0.1 + .", "label": "", "metadata": {}, "score": "105.0665"}
{"text": "Taxes on corporate income .......................... ( 2.0 ) ( 1.8 ) ( 1.8 ) ( 2.1 ) ( 2.2 ) ( 2.2 ) ( 2.0 ) ( 1.9 ) ( 1.9 ) .", "label": "", "metadata": {}, "score": "105.16388"}
{"text": "349 0.3- 0.1 + 061021 G96 0.4 + 0.5- .061003 461 0.3 + 0.5 + 061009349 0.1 + 0.1 + 061021 G96 0.4 + 0.7- .", "label": "", "metadata": {}, "score": "105.382355"}
{"text": "Addendum : Total Receipts and Expenditures .Current receipts ................................................20.2 18.0 17.2 17.0 17.9 18.9 19.2 19.1 .Capital transfer receipts ....................................... 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 .", "label": "", "metadata": {}, "score": "105.42525"}
{"text": "Environmental Protection Agency ...................... 1.0 0.9 0.8 0.7 0.5 0.5 0.5 0.5 0.5 .International Assistance Programs .................... 0.7 1.3 1.2 1.1 1.0 1.3 1.3 1.1 1.0 .", "label": "", "metadata": {}, "score": "105.43898"}
{"text": "Sharp , Jamilah ......27 713 89 100 189 54 0 14 47 0.3 13 .Total ............... 27 5400 513 697 1210 522 10 275 599 0.5 95 .", "label": "", "metadata": {}, "score": "105.53494"}
{"text": "Gardner , Nadirah .... 26 79 3.0 .Branch , Terra ....... 20 27 .741 Burris , Brandi ...... 26 73 2.8 .Gardner , Nadirah .... 56 79 .709", "label": "", "metadata": {}, "score": "105.58594"}
{"text": "SCORE BY PERIODS : 1st 2nd Total .Georgia Southwestern .......... 838 920 - 1758 .Opponents ..................... 885 990 - 1875 .DEADBALL REBOUNDS : OFF DEF TOTAL .", "label": "", "metadata": {}, "score": "105.71086"}
{"text": "585 1.1- 0.3- 061021 232 0.8- 0.0 .061002 G92 0.1 + 0.4- 061009585 0.2- 0.4- 061021 232 ( 2.5- 2.0- ) .061002 G92 0.8 + 1.3- 061009", "label": "", "metadata": {}, "score": "105.77084"}
{"text": "061003 J95 0.2- 0.4- 061011 673 ( 1.6 + 0.8- ) 061022J95 0.0 0.1- .061003 J95 0.1 + 0.4- 061011 673 ( 1.6 + 1.1- ) 061022", "label": "", "metadata": {}, "score": "105.87936"}
{"text": "Taxes on corporate income ..................................... ( 1.8 ) ( 1.4 ) ( 1.7 ) ( 2.0 ) ( 2.5 ) ( 2.9 ) ( 2.7 ) ( 2.5 ) .", "label": "", "metadata": {}, "score": "105.96367"}
{"text": "061003 H06 0.6 + 0.0 061013 850 0.2 + 0.3 + 061025 372 1.4- 0.1 + .061003 H06 0.2 + 0.2- 061013 850 0.3 + 0.0 061025 372 0.9- 0.3 + .", "label": "", "metadata": {}, "score": "106.02593"}
{"text": "Thomas , Krystal ..... 13 29 42 24 0 7 19 0.4 14 7 20 27 17 0 4 12 0.3 7 .Smith , Brittany ..... 5 6 11 12 0 3 7 0.4 4 2 0 2 5 0 1 0 0.0 0 .", "label": "", "metadata": {}, "score": "106.10589"}
{"text": "Pullen , Cherelle .... 26 22 0.8 .Billings , Tiandra ... 2 9 .222 .Thomas , Krystal ..... 4 19 .211 3-POINT FGS MADE G Made Made / G .", "label": "", "metadata": {}, "score": "106.15833"}
{"text": "11/29/08 3:00pm vs Puerto Rico - Bayamon W 71 - 61 76 ( 16)Reynolds , Brittany ( 11)Reynolds , Brittany .( 16)Burris , Brandi .", "label": "", "metadata": {}, "score": "106.28359"}
{"text": "11 Corbett , Clarissa G JR Y .12 Branch , Terra G FR Y .14 Elkins , Sylvia G FR Y .15 Reynolds , Brittany G JR Y .", "label": "", "metadata": {}, "score": "106.3191"}
{"text": "Elkins , Sylvia ...... 6 27 .222 Burris , Brandi ...... 26 106 4.1 .James , Monica ....... 5 23 .217Sharp , Jamilah ...... 27 82 3.0 .", "label": "", "metadata": {}, "score": "106.32068"}
{"text": "Gardner , Nadirah .... 26 56 2.2 .Elkins , Sylvia ...... 2 4 .500 Burris , Brandi ...... 26 56 2.2 .James , Monica ....... 2 6 .333", "label": "", "metadata": {}, "score": "106.33983"}
{"text": "56 - 73 .767 37 75 112 4.3 72 2 29 86 15 38 291 11.2 . 10 Pullen , Cherelle ... 26 - 1 240 9.2 7 - 39 .179 3 - 22 .136 6 - 6 1.000 6 27 33 1.3 21 0 21 27 0 17 23 0.9 .", "label": "", "metadata": {}, "score": "106.78523"}
{"text": "J95 0.5- 0.0 061017 048 0.7 + 0.7- 061121 850 ( 4.5 + 1.4- ) .061007J95 0.4- 0.0 061017 048 0.6 + 0.3- 061122 850 ( 3.6- 0.2 + ) .", "label": "", "metadata": {}, "score": "107.032005"}
{"text": "Total receipts ..................................... 17.9 17.8 18.4 18.5 19.1 19.2 19.9 19.6 18.4 .Current expenditures ................................. 20.6 20.8 20.2 19.8 19.4 20.6 21.4 22.5 23.4 .", "label": "", "metadata": {}, "score": "107.368164"}
{"text": "Thomas , Krystal ..... 22 26 - 83 .313 4 - 19 .211 8 - 14 .571 64 2.9 .Smith , Brittany ..... 8 3 - 9 .333 0 - 0 .000 2 - 6 .333 8 1.0 .", "label": "", "metadata": {}, "score": "107.48306"}
{"text": "Veterans Affairs ..................................... 3.9 3.6 3.4 3.2 3.1 3.0 2.8 2.7 2.7 .Corps of Engineers ................................... 0.6 0.5 0.5 0.4 0.4 0.4 0.3 0.3 0.3 .", "label": "", "metadata": {}, "score": "107.64482"}
{"text": "Education ............................................ 0.8 0.9 0.8 1.0 1.8 2.3 2.3 2.2 2.3 .Energy ............................................... 2.6 2.4 2.3 2.2 1.7 1.4 1.4 1.3 1.2 .Health and Human Services ............................ 3.3 3.7 3.9 4.0 4.2 6.1 7.3 8.4 8.9 .", "label": "", "metadata": {}, "score": "107.69948"}
{"text": "Opponents ..................... 87 5 92 .Georgia Southwestern Combined Team Statistics ( as of Feb 28 , 2009 ) .All games . . .RECORD : OVERALL HOME AWAY NEUTRAL .", "label": "", "metadata": {}, "score": "107.967636"}
{"text": "Environmental Protection Agency ...................... 0.3 0.3 0.5 0.8 0.8 0.8 1.2 1.1 0.9 .International Assistance Programs .................... 1.4 1.3 0.9 1.1 1.1 1.0 1.4 0.9 1.1 .", "label": "", "metadata": {}, "score": "108.01573"}
{"text": "Send Grover Norquist and Wayne LaPierre to the gallows before they destroy us .One wants to see the U.S. government fit in a bathtub and the other wants guns galore : the only way to stop a lunatic with a gun is another lunatic with a gun .", "label": "", "metadata": {}, "score": "108.01909"}
{"text": "Burris , Brandi ...... 37 75 112 72 2 29 86 0.3 19 25 61 86 57 2 23 66 0.3 19 .Pullen , Cherelle .... 6 27 33 21 0 21 27 0.8 8 6 17 23 12 0 10 19 0.5 4 .", "label": "", "metadata": {}, "score": "108.11723"}
{"text": "12/2/08 at Pensacola Christian W 86 - 39 - .12/30/08 at Valdosta State L 51 - 68 310 .3 Billings , Tiandra ... 10 - 0 4.9 .167 .222 .000 0.9 0.3 2 0 0.6 .", "label": "", "metadata": {}, "score": "108.136826"}
{"text": "PK11Y010 KC2011 12 17.72689 23 07 51.72 +26 44 34.5 19.1 TuEY007595 .PK11Y010 KC2011 12 17.74935 23 07 55.80 +26 44 02.2 uEY007J95 .PK11Y010 KC2011 12 17.75524 23 07 56.49 +26 43 55.5 19.6 TuEY007595 .", "label": "", "metadata": {}, "score": "108.17741"}
{"text": "3 POINT FG - ATT ........... 104 - 400 131 - 447 .3-point FG pct ......... .260 .293 .3-pt FG made per game .", "label": "", "metadata": {}, "score": "108.1985"}
{"text": "Burris , Brandi ...... 26 112 4.3 Burris , Brandi ...... 26 38 1.5 .Hadley , Arile ....... 27 115 4.3 Branch , Terra ....... 27 20 0.7 . . .", "label": "", "metadata": {}, "score": "108.25278"}
{"text": "Environmental Protection Agency ...................... 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 .International Assistance Programs .................... 0.7 0.4 0.8 0.9 0.8 0.8 0.7 0.7 0.6 .", "label": "", "metadata": {}, "score": "108.41499"}
{"text": "Opponents ..................... 885 990 - 1875 .Georgia Southwestern Overall Team Statistics ( as of Feb 28 , 2009 ) .All games .TEAM STATISTICS GSWW OPP .", "label": "", "metadata": {}, "score": "108.52105"}
{"text": "( 0.6 ) ( 0.7 ) ( 0.7 ) ( 0.6 ) ( 0.6 ) ( 0.6 ) ( 0.6 ) ( 0.6 ) ( 0.6 ) .", "label": "", "metadata": {}, "score": "108.83219"}
{"text": "ave 16.43 ! ! !Global equities strong , ex - Korea : UK +0.4 % vs +0.9 % !vs +0.7 % vs -0.2 % vs +0.7 % ; France +0.7 % vs -0.2 % vs +0.7 % vs -0.3 % vs +0.3 % ; Germany +0.9 % vs flat vs +0.9 % vs +0.4 % vs +0.5 % ; Japan +3.6 % ! ! !", "label": "", "metadata": {}, "score": "108.96416"}
{"text": "061003 G92 0.6 + 0.3 + 061013 850 0.0 0.1 + 061025 349 0.9- 0.0 . 061003 G92 1.3 + 0.6- 061013 H06 1.0 + 0.6- 061025 349 1.0- 0.2 + .", "label": "", "metadata": {}, "score": "108.99486"}
{"text": "Veterans Affairs ..................................... 2.7 2.6 2.3 2.4 2.5 2.5 2.6 2.5 2.4 .Corps of Engineers ................................... 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 .", "label": "", "metadata": {}, "score": "109.294785"}
{"text": "13 29 42 1.9 24 0 7 19 2 8 64 2.9 .32 Smith , Brittany .... 8 - 0 37 4.6 3 - 9 .333 0 - 0 .000 2 - 6 .333 5 6 11 1.4 12 0 3 7 0 4 8 1.0 .", "label": "", "metadata": {}, "score": "109.62261"}
{"text": "Veterans Affairs ..................................... 5.2 4.9 4.8 4.8 4.4 4.2 3.9 4.2 4.4 .Corps of Engineers ................................... 0.9 1.0 0.9 1.0 0.9 0.8 0.7 0.7 0.6 .", "label": "", "metadata": {}, "score": "109.66922"}
{"text": "Subsidies ............................................ 0.4 0.3 0.3 0.2 0.3 0.4 0.4 0.4 0.4 .Wage disbursements less accruals ..................... .........-0.1 0.1 ......... ......... ......... ......... ......... ......... .", "label": "", "metadata": {}, "score": "109.7018"}
{"text": "Sharp , Jamilah ...... 89 100 189 54 0 14 47 0.3 13 66 74 140 42 0 11 35 0.3 13 .Total ............... 513 697 1210 522 10 275 599 0.5 95 370 519 889 392 8 194 455 0.4 79 .", "label": "", "metadata": {}, "score": "109.88777"}
{"text": "349 0.6- 0.1 + 061017 G92 ( 2.8- 2.5 + ) 061123 850 0.0 0.7 + .061007300 1.1- 0.1 + 061018 379 1.0 + 0.8- 061124 G92 ( 4.0 + 0.5 + ) .", "label": "", "metadata": {}, "score": "109.99518"}
{"text": "FOULS G No .Per / G TURNOVERS GNo .TO / G .Wiltz , Whitley ...... 26 74 2.8 Gardner , Nadirah .... 26 99 3.8 .", "label": "", "metadata": {}, "score": "110.21695"}
{"text": "44.8 10.2 271 69 65.1 20 .360 .245 .66944.5 9.7 183 53 62.7 .Opponents ........... 27 .423 .293 .65238.4 14.1 275 87 69.4 20 .430 .291 .645", "label": "", "metadata": {}, "score": "110.34986"}
{"text": "36.9 33.7 30.5 28.9 25.5 23.6 22.7 23.3 22.3 .Education ............................................ 2.4 2.4 2.3 2.1 2.2 2.1 2.1 2.1 2.1 .Energy ............................................... 1.0 1.0 0.9 0.8 1.0 1.0 1.1 1.2 1.4 .", "label": "", "metadata": {}, "score": "110.4183"}
{"text": "Athens and Shibboleth are access management services that provide single sign - on to protected resources .They replace the multiple user names and passwords necessary to access subscription - based content with a single user name and password that can be entered once per session .", "label": "", "metadata": {}, "score": "110.45033"}
{"text": "Defense -- Military ...............................................19.2 18.8 19.7 20.1 19.4 17.8 16.9 16.2 .Education ....................................................... 2.9 3.5 2.4 2.0 2.1 2.1 2.0 2.0 .Energy .......................................................... 0.9 0.7 0.8 0.8 0.8 0.8 0.7 0.7 .", "label": "", "metadata": {}, "score": "110.50995"}
{"text": "44 Sharp , Jamilah ..... 27 - 27 713 26.4 82 - 198 .414 3 - 18 .167 31 - 55 .564 89 100 189 7.0 54 0 14 47 7 14 198 7.3 .", "label": "", "metadata": {}, "score": "110.73488"}
{"text": "Is this something to be proud of ?That does n't even consider the accidental or random shootings - a hunter accidentally shot and killed someone he thought was an animal .", "label": "", "metadata": {}, "score": "110.75967"}
{"text": "Housing and Urban Development ........................ 0.8 -0.5 0.1 0.4 1.8 2.0 2.1 0.4 1.2 .Interior ............................................. 0.6 0.7 0.6 0.6 0.6 0.5 0.5 0.6 0.6 .", "label": "", "metadata": {}, "score": "110.816025"}
{"text": "( 8)Wiltz , Whitley .( 8)Hadley , Arile .( 8)Burris , Brandi .( 8)Corbett , Clarissa .( 4)Wiltz , Whitley .( 4)Reynolds , Brittany .", "label": "", "metadata": {}, "score": "110.867775"}
{"text": "Thomas , Krystal ..... 22 210 13 29 42 24 0 7 19 0.4 14 .Smith , Brittany ..... 8 37 5 6 11 12 0 3 7 0.4 4 .", "label": "", "metadata": {}, "score": "110.91684"}
{"text": "Smith , Brittany ..... 2 6 .333Sharp , Jamilah ...... 27 31 1.1 . . .POINTS G Pts Pts / G POINTS AVERAGE G Pts Avg / G .", "label": "", "metadata": {}, "score": "111.08243"}
{"text": "Hadley , Arile ....... 27 115 4.3 Burris , Brandi ...... 26 29 1.1 .Burris , Brandi ...... 26 112 4.3 Corbett , Clarissa ... 26 28 1.1 .", "label": "", "metadata": {}, "score": "111.58081"}
{"text": "15 Reynolds , Brittany .20 Wiltz , Whitley ..... 26 - 23 728 28.0 71 - 193 .368 18 - 57 .316 36 - 54 .667 85 89 174 6.7 74 2 30 66 11 39 196 7.5 .", "label": "", "metadata": {}, "score": "111.74208"}
{"text": "Libor update : 0.237 % 3 mos ., 0.428 % vs 0.425 % , 6 mos .Foreign bond yields higher - except problem countries : Germany 1.29 % +5 ; UK 1.80 % +9 ! ! ! ; France 1.82 % +3 , Italy 3.85 % -6 ; Spain 4.05 % -3 ; Portugal 5.43 % +6 ; Greece 9.53 % -6 vs 9.58 % vs 9.68 % vs 10.09 % ! ! !", "label": "", "metadata": {}, "score": "111.9743"}
{"text": "S&P traded to a record high of 1618.46 Friday .Today it broke it with a whopping 1619.77 ? ? ?Then it close up just 3 points with a total trading range of just 5 points ? ? ?", "label": "", "metadata": {}, "score": "112.027756"}
{"text": "Environmental Protection Agency ................................. 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 .International Assistance Programs ............................... 0.6 0.5 0.6 0.6 0.6 0.6 0.6 0.6 .", "label": "", "metadata": {}, "score": "112.097885"}
{"text": "Georgia Southwestern Team Roster ( as of Feb 28 , 2009 ) .All games .Site : Storm Dome .Conference : Peach Belt .", "label": "", "metadata": {}, "score": "112.54425"}
{"text": "Wiltz , Whitley ...... 26 - 23 28.0 .368 .316 .667 6.7 1.2 39 11 7.5 20 - 17 28.4 .362 .356 .6006.8 1.2 28 9 7.1 .", "label": "", "metadata": {}, "score": "112.62604"}
{"text": "Housing and Urban Development ........................ 1.8 2.2 2.2 2.0 2.0 2.0 3.0 1.4 1.5 .Interior ............................................. 0.8 0.8 0.7 0.5 0.6 0.6 0.5 0.5 0.5 .", "label": "", "metadata": {}, "score": "112.94623"}
{"text": "J77 Golden Hill Observatory , Stourton Caundle .Observer R. Miles .0.10-m .f/2.8 refractor + CCD .J95 Great Shefford .Observer P. Birtwhistle . 0.40-m f/6.0 Schmidt - Cassegrain .", "label": "", "metadata": {}, "score": "113.314896"}
{"text": "Housing and Urban Development ................................... 1.7 1.8 1.9 1.7 1.8 1.6 1.7 2.0 .Interior ........................................................ 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.4 .Justice ......................................................... 0.8 0.8 1.0 0.9 1.0 1.1 1.0 1.3 .", "label": "", "metadata": {}, "score": "113.42767"}
{"text": "Treasury ........................................................16.6 17.5 17.6 18.1 18.6 19.2 19.2 19.2 .Veterans Affairs ................................................ 2.8 2.6 2.6 2.9 2.9 2.9 3.1 2.8 .Corps of Engineers .............................................. 0.2 0.3 0.3 0.2 0.2 0.2 0.2 0.2 .", "label": "", "metadata": {}, "score": "113.58453"}
{"text": "Luer - Lok \u00ae system : .Attach a large bore needle , e.g. , 18 gauge , to the syringe 's universal Luer\u2011Lok \u00ae .", "label": "", "metadata": {}, "score": "113.74329"}
{"text": "No sales tax on internet transactions except those with a presence in a state ?The internet does not need any more subsidy and that is what it is ... at the expense of the merchants who hire REAL people and support local economies and even the big retailers who also sell over the internet .", "label": "", "metadata": {}, "score": "113.745575"}
{"text": "If your institution uses Athens or Shibboleth authentication , please contact your site administrator to receive your user name and password . 1 Division of Cardiology , Ospedale \" Maggiore della Carit\u00e0 , \" Eastern Piedmont University , Novara , Italy , and Centro di Biotecnologie per la Ricerca Medica Applicata ( BRMA ) , Eastern Piedmont University , Novara , Italy .", "label": "", "metadata": {}, "score": "114.095406"}
{"text": "349 0.5- 0.4 + 061017 G92 ( 1.8- 3.9 + ) 061123 850 ( 3.3 + 0.2 + ) .061007349 0.5- 0.2 + 061017 G92 ( 2.8- 3.1 + ) 061123 850 ( 2.5 + 0.3 + ) .", "label": "", "metadata": {}, "score": "114.21802"}
{"text": "Turnovers per game ..... 22.2 20.8 .Turnover margin ........ -1.4 - .Assist / turnover ratio .STEALS ................... 271275 .Steals per game ........ 10.0 10.2 .", "label": "", "metadata": {}, "score": "114.24395"}
{"text": "Treasury ............................................. 9.7 9.3 12.3 13.1 12.6 11.7 10.7 11.7 11.8 .Veterans Affairs ..................................... 4.6 4.6 4.9 5.0 5.0 5.0 4.1 4.4 4.1 .Corps of Engineers ................................... 0.6 0.6 0.7 0.6 0.6 0.6 0.6 0.6 0.6 .", "label": "", "metadata": {}, "score": "114.567535"}
{"text": "No .S / G .Reynolds , Brittany .27 192 7.1 Gardner , Nadirah .... 26 51 2.0 .Sharp , Jamilah ......27 189 7.0 Reynolds , Brittany .", "label": "", "metadata": {}, "score": "114.86463"}
{"text": "Branch , Terra ....... 27 59 2.2 .Branch , Terra ....... 19 59 .322Wiltz , Whitley ...... 26 57 2.2 .Wiltz , Whitley ...... 18 57 .316 Gardner , Nadirah .... 26 57 2.2 .", "label": "", "metadata": {}, "score": "115.64729"}
{"text": "Environmental Protection Agency ...................... 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 .General Services Administration ...................... 0.4 0.4 0.4 0.5 0.4 0.4 0.3 0.3 0.3 .", "label": "", "metadata": {}, "score": "115.73517"}
{"text": "Housing and Urban Development ........................ 1.8 1.7 1.6 1.7 1.8 1.8 1.8 1.9 1.6 .Interior ............................................. 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.4 .", "label": "", "metadata": {}, "score": "115.76788"}
{"text": "Wiltz , Whitley ...... 26 196 7.5 Sharp , Jamilah ...... 27 198 7.3 .Branch , Terra ....... 27 161 6.0 Branch , Terra ....... 27 161 6.0 .", "label": "", "metadata": {}, "score": "116.07611"}
{"text": "Circulation1999;100,1593 - 1601 .Copyright in the material you requested is held by the American College of Chest Physicians ( unless otherwise noted ) .This email ability is provided as a courtesy , and by using it you agree that that you are requesting the material solely for personal , non - commercial use , and that it is subject to the American College of Chest Physicians ' Terms of Use .", "label": "", "metadata": {}, "score": "116.28927"}
{"text": "1.9 0.3 8 2 2.9 16 - 0 8.2 .217 .100 .6671.7 0.3 3 2 1.7 .Smith , Brittany ..... 8 - 0 4.6 .333 .000 .333 1.4 0.4 4 0 1.0 5 - 0 2.4 .000 .000 .000 0.4 0.2 1 0 0.0 .", "label": "", "metadata": {}, "score": "116.5399"}
{"text": "REBOUNDS ................. 1210 1038 .Rebounds per game ......44.8 38.4 .Rebounding margin ......+6.4 - .ASSISTS .................. 275 381 .Assists per game ....... 10.2 14.1 .", "label": "", "metadata": {}, "score": "116.69458"}
{"text": "Wiltz , Whitley ...... 26 18 0.7 .Pullen , Cherelle .... 3 22 .136 Gardner , Nadirah .... 26 12 0.5 .Reynolds , Brittany .", "label": "", "metadata": {}, "score": "116.721016"}
{"text": "Gardner , Nadirah .... 26 70 2.7 Burris , Brandi ...... 26 86 3.3 .Reynolds , Brittany .27 69 2.6 Wiltz , Whitley ...... 26 66 2.5 .", "label": "", "metadata": {}, "score": "117.15244"}
{"text": "27 7 0.3 .DEFENSIVE REBOUNDS G No .Avg / G MINUTES G No .Min / G .Reynolds , Brittany .27 119 4.4 Wiltz , Whitley ...... 26 728 28.0 .", "label": "", "metadata": {}, "score": "118.03373"}
{"text": "Wiltz , Whitley ...... 26 728 85 89 174 74 2 30 66 0.5 15 .Gardner , Nadirah .... 26 671 27 77 104 70 3 51 99 0.5 19 .", "label": "", "metadata": {}, "score": "118.13412"}
{"text": "TURNOVERS ................ 599 562 .Turnovers per game ..... 22.2 20.8 .Turnover margin ........ -1.4 - .Assist / turnover ratio .STEALS ................... 271", "label": "", "metadata": {}, "score": "118.25911"}
{"text": "Homeland Security ............................................... 1.6 2.6 1.8 1.5 1.4 1.2 1.1 1.1 .Housing and Urban Development ................................... 1.7 1.6 1.5 1.5 1.4 1.3 1.2 1.1 .", "label": "", "metadata": {}, "score": "118.85635"}
{"text": "Homeland Security .................................... 0.5 0.6 0.7 0.6 0.6 0.7 0.7 0.7 0.7 .Housing and Urban Development ........................ 1.3 1.6 1.5 1.8 2.3 1.9 1.4 1.4 1.7 .", "label": "", "metadata": {}, "score": "118.94209"}
{"text": "MPC@CFA.HARVARD.EDU .Observations : .PK11Y010 C2011 12 17.06325 23 05 56.18 +26 59 18.2 19.8 TrEY007G96 .PK11Y010 C2011 12 17.06519 23 05 56.61 +26 59 16.0 20.1 TrEY007G96 .", "label": "", "metadata": {}, "score": "119.0187"}
{"text": "NEUTRAL ................. 1 76 76 .TOTAL ................... 27 9023 334 .Georgia Southwestern Season Box Score ( as of Feb 28 , 2009 ) .", "label": "", "metadata": {}, "score": "119.23463"}
{"text": "Hadley , Arile ....... 27 89 3.3 Hadley , Arile ....... 27 89 3.3 .Thomas , Krystal ..... 22 64 2.9 Thomas , Krystal ..... 22 64 2.9 .", "label": "", "metadata": {}, "score": "119.563675"}
{"text": "FREE THROWS MADE G Made Made / G .Thomas , Krystal ..... 814 .571----------------------------------- .Sharp , Jamilah ...... 31 55 .564Reynolds , Brittany .", "label": "", "metadata": {}, "score": "119.63769"}
{"text": "Reynolds , Brittany .Wiltz , Whitley ......26 71 - 193 .368 18 - 57 .316 36 - 54 .667196 7.5 .Gardner , Nadirah .... 26 116 - 305 .380 12 - 57 .211 56 - 79 .709 300 11.5 .", "label": "", "metadata": {}, "score": "119.79144"}
{"text": "Wiltz , Whitley ...... 85 89 174 74 2 30 66 0.5 15 60 75 135 60 2 24 46 0.5 14 .Gardner , Nadirah .... 27 77 104 70 3 51 99 0.5 19 19 60 79 56 3 37 85 0.4 19 .", "label": "", "metadata": {}, "score": "119.96304"}
{"text": "The Judiciary ........................................ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 .Agriculture .......................................... 6.0 6.7 6.4 5.9 4.2 3.8 4.2 4.6 4.3 .Commerce ............................................. 0.2 0.3 0.6 0.6 0.4 0.3 0.3 0.3 0.4 .", "label": "", "metadata": {}, "score": "120.148895"}
{"text": "The Judiciary ........................................ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 .Agriculture .......................................... 4.1 4.8 4.1 3.8 4.7 4.8 5.2 5.7 6.6 .Commerce ............................................. 0.4 0.4 0.4 0.4 0.3 0.4 0.4 0.5 1.0 .", "label": "", "metadata": {}, "score": "120.17452"}
{"text": "Wiltz , Whitley ...... 26 89 3.4 Sharp , Jamilah ......27 713 26.4 .Gardner , Nadirah .... 26 77 3.0 Reynolds , Brittany .", "label": "", "metadata": {}, "score": "120.27638"}
{"text": "FT PERCENTAGE FT ATT Pct FREE THROW ATTEMPTS G Att Att / G .Pullen , Cherelle .... 6 6 1.000 Reynolds , Brittany .Burris , Brandi ......", "label": "", "metadata": {}, "score": "120.27725"}
{"text": "The Judiciary ........................................ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 .Agriculture .......................................... 6.3 5.9 6.1 6.1 6.5 4.9 5.9 5.9 4.9 .Commerce ............................................. 0.7 0.5 0.3 0.3 0.2 0.2 0.2 0.2 0.2 .", "label": "", "metadata": {}, "score": "120.392426"}
{"text": "Hadley , Arile ....... 19 27 .704Wiltz , Whitley ...... 26 54 2.1 .Wiltz , Whitley ...... 36 54 .667 .Reynolds , Brittany .", "label": "", "metadata": {}, "score": "120.50189"}
{"text": "Corps of Engineers .............................................. 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 .Other Defense -- Civil Programs ................................... 1.9 1.9 1.9 1.8 1.8 1.7 1.8 1.8 .", "label": "", "metadata": {}, "score": "120.61618"}
{"text": "The Judiciary ........................................ 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 .Agriculture .......................................... 4.1 4.2 3.7 4.1 4.1 4.5 4.1 3.7 3.5 .Commerce ............................................. 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 .", "label": "", "metadata": {}, "score": "120.77633"}
{"text": "( 13)Reynolds , Brittany .( 5)Reynolds , Brittany .( 5)Wiltz , Whitley .( 7)Sharp , Jamilah .HOME .................... 13 3892 299 .", "label": "", "metadata": {}, "score": "121.6566"}
{"text": "The Judiciary ................................................... 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 .Agriculture ..................................................... 3.3 3.3 3.7 4.2 3.7 3.4 3.4 3.1 .Commerce ........................................................ 0.2 0.2 0.3 0.4 0.3 0.3 0.3 0.3 .", "label": "", "metadata": {}, "score": "121.67846"}
{"text": "Wiltz , Whitley ...... 71 193 .368 ----------------------------------- .Smith , Brittany ..... 3 9 .333Gardner , Nadirah .... 26 116 4.5 .Thomas , Krystal ..... 26 83 .313", "label": "", "metadata": {}, "score": "121.86018"}
{"text": "Justice .............................................. 0.4 0.5 0.6 0.6 0.6 0.6 0.6 0.5 0.5 .Labor ................................................ 4.0 4.5 3.9 3.7 5.6 7.1 6.4 5.7 5.2 .State ................................................ 0.3 0.3 0.3 0.4 0.3 0.4 0.4 0.4 0.4 .", "label": "", "metadata": {}, "score": "121.93626"}
{"text": "Steals per game ........ 10.0 10.2 .BLOCKS ................... 69 87 .Blocks per game ........ 2.6 3.2 .WINNING STREAK ........... 1 - .Home win streak ........ 1 - .", "label": "", "metadata": {}, "score": "122.04573"}
{"text": "Labor ................................................ 3.7 3.2 2.9 2.6 2.4 2.3 2.3 2.3 2.5 .State ................................................ 0.4 0.5 0.4 0.5 0.5 0.4 0.4 0.3 0.3 .Transportation ....................................... 3.6 3.7 4.0 4.4 3.8 3.3 3.1 3.1 3.1 .", "label": "", "metadata": {}, "score": "122.051285"}
{"text": "Reynolds , Brittany .Wiltz , Whitley ...... 71 - 193 .368 18 - 57 .316 36 - 54 .667196 7.5 51 - 141 .362 16 - 45 .356", "label": "", "metadata": {}, "score": "122.08334"}
{"text": "A / G .Reynolds , Brittany .27 192 7.1 Reynolds , Brittany .Sharp , Jamilah ......27 189 7.0 Gardner , Nadirah .... 26 51 2.0 .", "label": "", "metadata": {}, "score": "122.440765"}
{"text": "National Science Foundation .......................... 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2 .Office of Personnel Management ....................... 2.5 2.5 2.7 2.7 2.6 2.7 2.5 2.4 2.7 .", "label": "", "metadata": {}, "score": "122.450775"}
{"text": "061006 204 0.0 0.0 061016 143 0.8 + 0.1- 061117 H06 ( 2.6 + 0.1- ) .061006J63 1.0 + 0.1- 061016 H06 0.4 + 0.2- 061118 232 1.4 + 1.0- . 061006", "label": "", "metadata": {}, "score": "122.67812"}
{"text": "National Science Foundation .......................... 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 .Office of Personnel Management ....................... 2.7 2.5 2.5 2.6 2.6 2.6 2.6 2.7 2.7 .", "label": "", "metadata": {}, "score": "122.78287"}
{"text": "Labor ................................................ 2.1 2.0 2.1 2.6 3.5 3.2 2.6 2.2 2.1 .State ................................................ 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.4 0.4 .Transportation ....................................... 2.2 2.1 2.0 2.1 2.1 2.2 2.3 2.3 2.3 .", "label": "", "metadata": {}, "score": "123.06326"}
{"text": "Justice ......................................................... 0.9 0.9 0.8 0.8 0.8 0.8 0.7 0.7 .Labor ........................................................... 1.9 1.6 1.7 1.8 1.6 1.6 1.6 1.6 .State ........................................................... 0.5 0.5 0.6 0.6 0.6 0.5 0.5 0.5 .", "label": "", "metadata": {}, "score": "124.08054"}
{"text": "Labor ................................................ 4.7 5.2 4.6 4.2 4.8 3.0 2.6 2.5 2.4 .State ................................................ 0.4 0.4 0.3 0.4 0.3 0.4 0.3 0.4 0.4 .Transportation ....................................... 2.9 3.1 3.1 2.4 2.3 2.4 2.4 2.5 2.3 .", "label": "", "metadata": {}, "score": "124.926994"}
{"text": "26 71 2.7 . . .3-POINT PERCENTAGE 3FG ATT Pct 3-POINT FG ATTEMPTS G Att Att / G .Reynolds , Brittany . 7 19 .368 Burris , Brandi ...... 26 83 3.2 .", "label": "", "metadata": {}, "score": "125.55664"}
{"text": "National Science Foundation .......................... 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 .Office of Personnel Management ....................... 1.5 1.6 1.9 2.1 2.1 2.2 2.5 2.4 2.4 .", "label": "", "metadata": {}, "score": "125.9142"}
{"text": "Legislative Branch .............................................. 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 .The Judiciary ................................................... 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 .Agriculture ..................................................... 3.5 3.5 3.2 3.1 3.0 3.0 3.0 3.0 .", "label": "", "metadata": {}, "score": "127.1517"}
{"text": "National Science Foundation ..................................... 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 .Office of Personnel Management .................................. 2.4 2.3 2.1 2.2 2.2 2.3 2.3 2.3 .", "label": "", "metadata": {}, "score": "129.22849"}
{"text": "061006 204 0.0 0.0 061016 104 1.2 + 0.5- 061113H06 ( 1.6 + 0.1 + ) .061006 204 0.1- 0.1- 061016 104 1.4 + 0.3- 061116", "label": "", "metadata": {}, "score": "129.67926"}
{"text": "Reynolds , Brittany .27 73 2.7 Wiltz , Whitley ...... 26 11 0.4 .Hadley , Arile ....... 27 57 2.1 Reynolds , Brittany .", "label": "", "metadata": {}, "score": "129.95508"}
{"text": "National Aeronautics and Space Administration ........ 1.2 2.3 3.5 4.3 4.4 3.4 2.7 2.3 1.9 .National Science Foundation .......................... 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.2 .", "label": "", "metadata": {}, "score": "130.11885"}
{"text": "State ........................................................... 0.4 0.3 0.4 0.4 0.4 0.5 0.4 0.5 .Transportation .................................................. 2.3 2.2 2.2 2.3 2.6 2.8 2.4 2.4 .Treasury ........................................................23.6 23.5 22.6 21.8 20.8 18.5 17.0 16.4 .", "label": "", "metadata": {}, "score": "131.92166"}
{"text": "PubMed .Copyright .\u00a9 Doepp et al .2005 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "135.10616"}
{"text": "Reynolds , Brittany .Hadley , Arile .......34 87 .391Burris , Brandi ...... 26 260 10.0 .Reynolds , Brittany .107 277 .386", "label": "", "metadata": {}, "score": "136.96431"}
{"text": "Reynolds , Brittany .27 294 10.9 Burris , Brandi ...... 26 291 11.2 .Burris , Brandi ...... 26 291 11.2 Reynolds , Brittany .", "label": "", "metadata": {}, "score": "142.83194"}
{"text": "Please refer to the American College of Chest Physicians ' Privacy Policy for further information .Copyright \u00a9 American College of Chest Physicians .All rights reserved .", "label": "", "metadata": {}, "score": "151.43066"}
